

ANNUAL STATEMENT

FOR THE YEAR ENDING DECEMBER 31, 2023 OF THE CONDITION AND AFFAIRS OF THE

Blue Cross Complete of Michigan LLC (Name)

	00572 ,00572 ent Period) ,(Prior Perior		pany Code11557	Employer's ID Number	47-2582248
Organized under the Laws o	fM	, ichigan	, State of Domicile	e or Port of Entry	Michigan
Country of Domicile			United States		
Licensed as business type:	Life, Accident & Health [Dental Service Corporatio Other []	n [] Vision S	y/Casualty [] Service Corporation [] O, Federally Qualified? Yo	· ·	,
Incorporated/Organized	12/18/201	4	Commenced Business	01/01/2	2003
Statutory Home Office		Center, Suite 1300 et and Number)	,	Southfield, MI, US (City or Town, State, Country a	
Main Administrative Office			200 Stevens D (Street and Numb		
	elphia, PA, US 19113 /n, State, Country and Zip Code)			215-937-8000 (Area Code) (Telephone Number)	
Mail Address	4000 Town Center, S (Street and Number or P		,	Southfield, MI, US 4807 (City or Town, State, Country and Zig	
Primary Location of Books a	`		200 \$	Stevens Drive	,
,	_		(Stre	et and Number)	
	elphia, PA, US 19113 /n, State, Country and Zip Code)		(An	215-937-8000 ea Code) (Telephone Number) (Extension	on)
Internet Web Site Address			MiBlueCrossComplete		,
Statutory Statement Contact	Michael A	Andrew Hendel	•	248-663-7329	
		(Name)	,	(Area Code) (Telephone Number) 248-663-7475 (Fax Number)	(Extension)
Name Michael John Burgoyr Kathy Combs Warne		Title reasurer resident	Robert Edward To	e potle, Esquire, ,	Title Secretary
Eileen Mary Coggins Cathy Ann Flowers		DIRECTORS Jane Engelman	OR TRUSTEES Tricia Ann	Keith Lyı	nda Marie Rossi
	PennsylvaniaPhiladelphia	SS			
above, all of the herein describe that this statement, together will liabilities and of the condition an and have been completed in acc may differ; or, (2) that state rule knowledge and belief, respective	d assets were the absolute print related exhibits, schedules d affairs of the said reporting cordance with the NAIC Annuals or regulations require differely. Furthermore, the scope of copy (except for formatting di	roperty of the said repo and explanations there entity as of the reportin I Statement Instructions ences in reporting not re this attestation by the	rting entity, free and clear frein contained, annexed or rag period stated above, and as and Accounting Practices a elated to accounting practice described officers also inclu-	said reporting entity, and that on om any liens or claims thereon, exercised to, is a full and true state of its income and deductions there and Procedures manual except to the and procedures, according to the des the related corresponding electratement. The electronic filing manual except to the statement.	cept as herein stated, and ment of all the assets and from for the period ended, ne extent that: (1) state law e best of their information, ctronic filing with the NAIC,
Michael John Treasu			ard Tootle, Esquire ecretary	Kathy Com Presi	
Subscribed and sworn to bday of	efore me this February, 2024		b. If 1. 2.	this an original filing? no: State the amendment number Date filed Number of pages attached	Yes [X] No []

ASSETS

1. Bonds (Schedule D). 2. Stocks (Schedule D): 2.1 Preferred stocks 2.2 Common stocks 3. Mortgage loans on real estate (Schedule B): 3.1 First liens 3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less 5. 0 encumbrances). 4.2 Properties held for the production of income (less \$ 0 encumbrances). 4.3 Properties held for sale (less 5. 0 encumbrances). 5. Cash (\$	360,803,502 360,803,502 0 453,585,126 251,075,917			
2. Stocks (Schedule D): 2.1 Preferred stocks 2.2 Common stocks 3. Mortgage loans on real estate (Schedule B): 3.1 First liens 3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$	Assets46,795,439045,986,185360,803,50200	Nonadmitted Assets	Net Admitted Assets (Cols. 1 - 2)	Net Admitted Assets
2. Stocks (Schedule D): 2.1 Preferred stocks 2.2 Common stocks 3. Mortgage loans on real estate (Schedule B): 3.1 First liens 3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$	46,795,439		(Cols. 1 - 2)	Assets
2. Stocks (Schedule D): 2.1 Preferred stocks 2.2 Common stocks 3. Mortgage loans on real estate (Schedule B): 3.1 First liens 3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$	46,795,439			
2. Stocks (Schedule D): 2.1 Preferred stocks 2.2 Common stocks 3. Mortgage loans on real estate (Schedule B): 3.1 First liens 3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$	360,803,502 360,803,502 0 453,585,126 251,075,917			
2.1 Preferred stocks 2.2 Common stocks 3. Mortgage loans on real estate (Schedule B): 3.1 First liens 3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$	45,986,185			
2.2 Common stocks 3. Mortgage loans on real estate (Schedule B): 3.1 First liens 3.2 Other than first liens. 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$	45,986,185			
3. Mortgage loans on real estate (Schedule B): 3.1 First liens 3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$	360,803,502			
3.1 First liens 3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$0 encumbrances). 4.2 Properties held for the production of income (less \$0 encumbrances). 4.3 Properties held for sale (less \$0 encumbrances). 5. Cash (\$268, 483,513 , Schedule E-Part 1), cash equivalents (\$86,082,256 , Schedule E-Part 2) and short-term investments (\$6,237,731 , Schedule DA). 6. Contract loans (including \$premium notes). 7. Derivatives (Schedule DB). 8. Other invested assets (Schedule BA) 9. Receivables for securities 10. Securities lending reinvested collateral assets (Schedule DL). 11. Aggregate write-ins for invested assets 12. Subtotals, cash and invested assets (Lines 1 to 11) 13. Title plants less \$charged off (for Title insurers only). 14. Investment income due and accrued 15. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$	360,803,502 0 0 453,585,126 251,075,917			
3.2 Other than first liens 4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$	360,803,502 0 0 453,585,126 251,075,917			
4. Real estate (Schedule A): 4.1 Properties occupied by the company (less \$				
4.1 Properties occupied by the company (less \$	360,803,502			
\$	360,803,502			
\$	360,803,502			
4.2 Properties held for the production of income (less \$	360,803,502			
(less \$0 encumbrances) 4.3 Properties held for sale (less \$0 encumbrances) 5. Cash (\$268, 483,513 , Schedule E-Part 1), cash equivalents (\$86,082,258 , Schedule E-Part 2) and short-term investments (\$6,237,731 , Schedule DA). 6. Contract loans (including \$premium notes) 7. Derivatives (Schedule DB). 8. Other invested assets (Schedule BA) 9. Receivables for securities 10. Securities lending reinvested collateral assets (Schedule DL) 11. Aggregate write-ins for invested assets 12. Subtotals, cash and invested assets (Lines 1 to 11) 13. Title plants less \$charged off (for Title insurers only) 14. Investment income due and accrued 15. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$	360,803,502			
4.3 Properties held for sale (less \$	360,803,502			
\$	360,803,502			
5. Cash (\$	360,803,502			
(\$				
investments (\$ 6,237,731 , Schedule DA). 6. Contract loans (including \$ premium notes). 7. Derivatives (Schedule DB). 8. Other invested assets (Schedule BA). 9. Receivables for securities. 10. Securities lending reinvested collateral assets (Schedule DL). 11. Aggregate write-ins for invested assets. 12. Subtotals, cash and invested assets (Lines 1 to 11). 13. Title plants less \$ charged off (for Title insurers only). 14. Investment income due and accrued. 15. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection. 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ earned but unbilled premiums). 15.3 Accrued retrospective premiums (\$ earned but contracts subject to redetermination (\$) and contracts subject to redetermination (\$) 16. Reinsurance: 16.1 Amounts recoverable from reinsurers 16.2 Funds held by or deposited with reinsured companies 16.3 Other amounts receivable under reinsurance contracts 17. Amounts receivable relating to uninsured plans. 18.1 Current federal and foreign income tax recoverable and interest thereon 18.2 Net deferred tax asset. 19. Guaranty funds receivable or on deposit 20. Electronic data processing equipment and software. 21. Furniture and equipment, including health care delivery assets (\$)				
6. Contract loans (including \$ premium notes) 7. Derivatives (Schedule DB)				
6. Contract loans (including \$ premium notes) 7. Derivatives (Schedule DB)				
7. Derivatives (Schedule DB). 8. Other invested assets (Schedule BA). 9. Receivables for securities. 10. Securities lending reinvested collateral assets (Schedule DL). 11. Aggregate write-ins for invested assets. 12. Subtotals, cash and invested assets (Lines 1 to 11). 13. Title plants less \$	0 0 453,585,126 995,571 251,075,917			
8. Other invested assets (Schedule BA) 9. Receivables for securities 10. Securities lending reinvested collateral assets (Schedule DL) 11. Aggregate write-ins for invested assets 12. Subtotals, cash and invested assets (Lines 1 to 11) 13. Title plants less \$	995,571			
9. Receivables for securities 10. Securities lending reinvested collateral assets (Schedule DL). 11. Aggregate write-ins for invested assets 12. Subtotals, cash and invested assets (Lines 1 to 11). 13. Title plants less \$ charged off (for Title insurers only). 14. Investment income due and accrued 15. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ earned but unbilled premiums). 15.3 Accrued retrospective premiums (\$) and contracts subject to redetermination (\$) and contracts subject to redetermination (\$) 16. Reinsurance: 16.1 Amounts recoverable from reinsurers 16.2 Funds held by or deposited with reinsured companies 16.3 Other amounts receivable under reinsurance contracts 17. Amounts receivable relating to uninsured plans 18.1 Current federal and foreign income tax recoverable and interest thereon 18.2 Net deferred tax asset. 19. Guaranty funds receivable or on deposit 20. Electronic data processing equipment and software. 21. Furniture and equipment, including health care delivery assets (\$)		0		
10. Securities lending reinvested collateral assets (Schedule DL). 11. Aggregate write-ins for invested assets 12. Subtotals, cash and invested assets (Lines 1 to 11). 13. Title plants less \$		0		
11. Aggregate write-ins for invested assets 12. Subtotals, cash and invested assets (Lines 1 to 11) 13. Title plants less \$	995,571	0		
12. Subtotals, cash and invested assets (Lines 1 to 11) 13. Title plants less \$	995,571	0		
13. Title plants less \$	251,075,917		0 995,571	0
only). 14. Investment income due and accrued 15. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$	251,075,917		995,571	417 ,848
14. Investment income due and accrued 15. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$	251,075,917		995,571	417 ,848
15. Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$	251,075,917			
15.1 Uncollected premiums and agents' balances in the course of collection			251,075,9170	117,635,801
15.1 Uncollected premiums and agents' balances in the course of collection			251,075,9170	117,635,801
collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$			251,075,9170	117,635,801
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$			0	
deferred and not yet due (including \$			0	n
but unbilled premiums) 15.3 Accrued retrospective premiums (\$			0	٥
15.3 Accrued retrospective premiums (\$			0	n
contracts subject to redetermination (\$				0
16. Reinsurance: 16.1 Amounts recoverable from reinsurers 16.2 Funds held by or deposited with reinsured companies 16.3 Other amounts receivable under reinsurance contracts 17. Amounts receivable relating to uninsured plans 18.1 Current federal and foreign income tax recoverable and interest thereon 18.2 Net deferred tax asset 19. Guaranty funds receivable or on deposit 20. Electronic data processing equipment and software 21. Furniture and equipment, including health care delivery assets (\$				
16.1 Amounts recoverable from reinsurers			0	0
16.2 Funds held by or deposited with reinsured companies 16.3 Other amounts receivable under reinsurance contracts 17. Amounts receivable relating to uninsured plans 18.1 Current federal and foreign income tax recoverable and interest thereon 18.2 Net deferred tax asset 19. Guaranty funds receivable or on deposit 20. Electronic data processing equipment and software 21. Furniture and equipment, including health care delivery assets (\$)				
16.2 Funds held by or deposited with reinsured companies 16.3 Other amounts receivable under reinsurance contracts 17. Amounts receivable relating to uninsured plans 18.1 Current federal and foreign income tax recoverable and interest thereon 18.2 Net deferred tax asset 19. Guaranty funds receivable or on deposit 20. Electronic data processing equipment and software 21. Furniture and equipment, including health care delivery assets (\$)			0	0
16.3 Other amounts receivable under reinsurance contracts 17. Amounts receivable relating to uninsured plans 18.1 Current federal and foreign income tax recoverable and interest thereon 18.2 Net deferred tax asset 19. Guaranty funds receivable or on deposit 20. Electronic data processing equipment and software 21. Furniture and equipment, including health care delivery assets (\$)				0
17. Amounts receivable relating to uninsured plans 18.1 Current federal and foreign income tax recoverable and interest thereon 18.2 Net deferred tax asset				0
18.1 Current federal and foreign income tax recoverable and interest thereon 18.2 Net deferred tax asset. 19. Guaranty funds receivable or on deposit. 20. Electronic data processing equipment and software. 21. Furniture and equipment, including health care delivery assets (\$)				0
18.2 Net deferred tax asset. 19. Guaranty funds receivable or on deposit				
Guaranty funds receivable or on deposit				0
Electronic data processing equipment and software				909,585
21. Furniture and equipment, including health care delivery assets (\$				0
(\$)			0	0
	675 , 137	675 , 137	0	0
22. Net adjustment in assets and liabilities due to foreign exchange rates				0
23. Receivables from parent, subsidiaries and affiliates				0
24. Health care (\$3,081,707) and other amounts receivable			3,081,707	
25. Aggregate write-ins for other-than-invested assets				0
	1 , 1 50 , 408	1,130,409		
26. Total assets excluding Separate Accounts, Segregated Accounts and	740 500 070	0 550 000	740 045 050	E40 040 400
Protected Cell Accounts (Lines 12 to 25)	7 10,566,878	3,550,928	713,015,950	512,042,193
27. From Separate Accounts, Segregated Accounts and Protected				
Cell Accounts			0	0
28. Total (Lines 26 and 27)	716,566,878	3,550,928	713,015,950	512,042,193
DETAILS OF WRITE-INS				<u></u>
1101.			0	0
1102.				
		i i	i	^
1198. Summary of remaining write-ins for Line 11 from overflow page		0	i	0
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)	0	· · · · · · · · · · · · · · · · · · ·	0	0
2501. Prepaid Expenses		788,254		0
2502. Leasehold Improvement	788 , 254	898,717		0
2503. Deposits		090,/1/		0
2598. Summary of remaining write-ins for Line 25 from overflow page	898,717			
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	898 ,717 51 ,518	51,518		0

LIABILITIES, CAPITAL AND SURPLUS

	•		Prior Year		
		1 Covered	2 Uncovered	3 Total	4 Total
1	Claims unpaid (less \$ reinsurance ceded)		Uncovered		
	Accrued medical incentive pool and bonus amounts				
2. 3.	Unpaid claims adjustment expenses			i	
	Aggregate health policy reserves, including the liability of	2,000,002		2,000,002	2,011,00J
ļ	\$ for medical loss ratio rebate per the Public				
	Health Service Act	22.385.341		22.385.341	0
5.	Aggregate life policy reserves				0
6.	Property/casualty unearned premium reserves				0
7.	Aggregate health claim reserves.				0
8.	Premiums received in advance				0
9.	General expenses due or accrued				
10.1	Current federal and foreign income tax payable and interest thereon (including	, ,		, ,	
	\$ on realized capital gains (losses))	3,980,960		3,980,960	2,782,782
10.2	Net deferred tax liability				
l	Ceded reinsurance premiums payable				
1	Amounts withheld or retained for the account of others				
13.	Remittances and items not allocated				
14.					
	interest thereon \$ (including				
	\$ current)				
15.	Amounts due to parent, subsidiaries and affiliates	15,215,081		15,215,081	9,232,060
16.	Derivatives		0	0	0
17.	Payable for securities			0	0
18.	Payable for securities lending			0	0
19.	Funds held under reinsurance treaties (with \$				
	authorized reinsurers, \$ unauthorized				
	reinsurers and \$ certified reinsurers)			0	0
20.	Reinsurance in unauthorized and certified (\$)				
	companies.				0
21.	Net adjustments in assets and liabilities due to foreign exchange rates				0
22.	Liability for amounts held under uninsured plans			0	0
23.	Aggregate write-ins for other liabilities (including \$				
	current)	i i	i	i	
24.	Total liabilities (Lines 1 to 23)				
25.	Aggregate write-ins for special surplus funds				0
26.	Common capital stock				
27.	Preferred capital stock				
28.	Gross paid in and contributed surplus		1		
29.	Surplus notes				
30.	Aggregate write-ins for other-than-special surplus funds		i		0
31.	Unassigned funds (surplus)	XXX	XXX	182,595,108	123 , 539 , 305
32.	Less treasury stock, at cost:				
	32.1shares common (value included in Line 26				
	\$	XXX	XXX		0
	32.2shares preferred (value included in Line 27				
İ	\$)				0
	, , ,			236,595,109	
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	713,015,950	512,042,193
İ	Stale Dated Checks	333,934		333,934	410,273
2302.	Insurance Provider Assessment				18,046,665
2303.					0
2398.	Summary of remaining write-ins for Line 23 from overflow page		0	0	0
2399.	Totals (Lines 2301 through 2303 plus 2398) (Line 23 above)	17,593,697	0	17,593,697	18,456,938
2501.		xxx	xxx		0
2502.		xxx	xxx		0
2503.		xxx	xxx		0
2598.	Summary of remaining write-ins for Line 25 from overflow page	xxx	xxx	0	0
2599.	Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	xxx	xxx	0	0
3001.	\\\				
3002.					
			i		
3003.	Summary of remaining write ine for Line 20 from everflow page				^
3098.	Summary of remaining write-ins for Line 30 from overflow page				0
3099.	Totals (Lines 3001 through 3003 plus 3098) (Line 30 above)	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

		Current	Year	Prior Year
		1 Uncovered	2 Total	3 Total
1	Member Months		4,222,630	
	Net premium income (including \$	1	l l	
	Change in unearned premium reserves and reserve for rate credits	1		
	Fee-for-service (net of \$medical expenses)	1		0
	Risk revenue			
		l l		
	Aggregate write-ins for other health care related revenues	i i	i	
	Total revenues (Lines 2 to 7)	1		
	,		1,000,907,001	1,300,091,401
· ·	ital and Medical:		676 077 145	602 405 002
i	Hospital/medical benefits	i i	1	682,405,092
İ	Other professional services	l l		55,535,937
	Outside referrals	l l		7,598,989
	Emergency room and out-of-area	1		69,532,186
	Prescription drugs	1		323,086,414
	Aggregate write-ins for other hospital and medical	1	1	8,686,302
	Incentive pool, withhold adjustments and bonus amounts	i i	′ ′ ′	
16.	Subtotal (Lines 9 to 15)	ļ0 <u> </u> .	1,273,661,084	1, 151,774,937
Less:				
i	Net reinsurance recoveries	1 1		0
18.	Total hospital and medical (Lines 16 minus 17)	0	1,273,661,084	1, 151,774,937
	Non-health claims (net)	1	ı	
i .	Claims adjustment expenses, including \$22,194,123 cost containment expenses	1	l l	
21.	General administrative expenses.		174,301,270	162,926,405
22.	Increase in reserves for life and accident and health contracts (including			
	\$increase in reserves for life only)		22,385,341	0
23.	Total underwriting deductions (Lines 18 through 22)	0 J.	1 ,510 ,305 ,517	1,350,655,133
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	xxx	48,681,534	30,036,268
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)		20,842,375	5,712,338
	Net realized capital gains (losses) less capital gains tax of \$143,016	1		917,218
	Net investment gains (losses) (Lines 25 plus 26)	1 1		6,629,556
	Net gain or (loss) from agents' or premium balances charged off [(amount recovered		, ,	, ,
	\$) (amount charged off \$		0	0
	Aggregate write-ins for other income or expenses			0
	Net income or (loss) after capital gains tax and before all other federal income taxes			
	(Lines 24 plus 27 plus 28 plus 29)	xxx	70,060,525	36,665,824
İ	Federal and foreign income taxes incurred	l I		7 ,676 ,235
İ	Net income (loss) (Lines 30 minus 31)	XXX	51,705,363	28,989,589
	S OF WRITE-INS	^^^	31,703,303	20,909,509
		, , , , , , , , , , , , , , , , , , ,		0
				0
		i i		
	Summary of remaining write-ins for Line 6 from overflow page	l l		0
	Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	XXX	0	0
0701.	Administrative Service Revenue	XXX	78,628	81,923
0702.		xxx		
0703.		xxx		
0798.	Summary of remaining write-ins for Line 7 from overflow page	xxx	0	0
0799.	Totals (Lines 0701 through 0703 plus 0798) (Line 7 above)	XXX	78,628	81,923
1401.	Alternative Medical Cost		4,656,402	5 , 385 , 625
1402.	Consumer Incentives		285,539	296,306
	PCMH Passthrough Expense	1	3,179,558	3,004,423
1498.	Summary of remaining write-ins for Line 14 from overflow page	ļ0 ļ.	1,651,250	(52)
	Totals (Lines 1401 through 1403 plus 1498) (Line 14 above)	0	9,772,749	8,686,302
	, , , , , , , , , , , , , , , , , , , ,			
2902.				
	Summary of remaining write-ins for Line 29 from overflow page		0	Λ
	Totals (Lines 2901 through 2903 plus 2998) (Line 29 above)	0	0	0
∠ ∂∂∂.	10tais (Enics 2001 tillough 2000 plus 2000) (Ellie 20 above)	. 0 [U	U

STATEMENT OF REVENUE AND EXPENSES (Continued)

		1 Current Year	2 Prior Year
		Guirone Four	Thor rour
	CAPITAL & SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	177 , 539 , 306	152,091,212
34.	Net income or (loss) from Line 32	51,705,363	28,989,589
35.	Change in valuation basis of aggregate policy and claim reserves		0
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$	3,098,037	(1,552,861)
37.	Change in net unrealized foreign exchange capital gain or (loss)		0
38.	Change in net deferred income tax	2,852,915	365,761
39.	Change in nonadmitted assets	1,399,488	624 , 169
40.	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles		0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)		0
	44.3 Transferred to surplus		0
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital		0
46.	Dividends to stockholders		0
47.	Aggregate write-ins for gains or (losses) in surplus	0	(2,978,564)
48.	Net change in capital and surplus (Lines 34 to 47)	59,055,803	25,448,094
49.	Capital and surplus end of reporting year (Line 33 plus 48)	236,595,109	177,539,306
DETAIL	S OF WRITE-INS		
4701.	SSAP 3 (2021 year) Correction Of Error		(2,978,564)
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 through 4703 plus 4798) (Line 47 above)	0	(2,978,564)

CASH FLOW

	Cash from Operations	1 Current Year	2 Prior Year
1	Premiums collected net of reinsurance	1 ,425 ,468 ,307	1 201 201 679
	Net investment income	1 1 1 1 1 1 1 1 1 1 1 1 1	
			81,923
	Miscellaneous income		1,286,672,36
	Total (Lines 1 through 3)		1, 117, 783, 342
	Benefit and loss related payments		
	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		188,911,49
	Commissions, expenses paid and aggregate write-ins for deductions		
	Dividends paid to policyholders		4 000 00
	Federal and foreign income taxes paid (recovered) net of \$, , , , , , , , , , , , , , , , , , , ,	4,900,00
	Total (Lines 5 through 9)		1,311,594,83
11.	Net cash from operations (Line 4 minus Line 10)	59,882,464	(24,922,47
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds		1,690,04
	12.2 Stocks		1 , 156 , 85
	12.3 Mortgage loans		
	12.4 Real estate	ı	
	12.5 Other invested assets	0	
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		(9,84
	12.7 Miscellaneous proceeds	0	
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	11,563,486	2,837,05
13.	. Cost of investments acquired (long-term only):		
	13.1 Bonds	18,894,278	39,632,59
	13.2 Stocks	2,289,161	42,151,84
	13.3 Mortgage loans		
	13.4 Real estate	0	
	13.5 Other invested assets	0	
	13.6 Miscellaneous applications		
	13.7 Total investments acquired (Lines 13.1 to 13.6)	21,183,439	81,784,43
14.	Net increase/(decrease) in contract loans and premium notes		
	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)		(78,947,38
	Cash from Financing and Miscellaneous Sources	(5,515,555)	(10,011,00
16	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	
	16.2 Capital and paid in surplus, less treasury stock.		
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied).		(327,82
17	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(== = 12)	(327.82
17.	·	\ 1,1 1,1	(021,02
10	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)		(104 107 67
			(104,197,07
19.	Cash, cash equivalents and short-term investments:	240 647 224	/1/ 0/E 00
	19.1 Beginning of year		
	19.2 End of year (Line 18 plus Line 19.1)	360,803,502	310,617,33

_

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Blue Cross Complete of Michigan LLC

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

Net premium income Change in unearned premium reserves and reserve for rate credit	Total 1.558.908.423	Compre (Hospital &		4	5	6	7	8	9	10	11	12	13	14
		_	3					1						1 1 1
				Medicare	Vision	Dental	Federal Employees Health	Title XVIII	Title XIX	Credit A&H	Disability	Long-Term	Other Health	Other
		Individual	Group	Supplement	Only	Only	Benefit Plan	Medicare	Medicaid 1.558.908.423	Credit A&n	Income	Care	Other Health	Non-Health
	1,000,000,120		0	0		0		ļ	1,000,000,420	0	0	0	l0	0
3. Fee-for-service (net of \$														
medical expenses)	0								<u> </u>					XXX
4. Risk revenue	0													xxx
Aggregate write-ins for other health care related revenues.	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
Aggregate write-ins for other non-health care related revenues	78.628	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	78.628
7. Total revenues (Lines 1 to 6)	1,558,987,051	0	0	0	0	0	0	L0	1,558,908,423	0	0	0	0	78,628
Hospital/medical benefits	676,877,145								676 ,877 ,145					XXX
9. Other professional services	95,247,925								95,247,925					XXX
10. Outside referrals	6,070,167								6,070,167					XXX
11. Emergency room and out-of-area	81,511,140								81,511,140					XXX
12. Prescription drugs	400,443,523								400,443,523					XXX
13. Aggregate write-ins for other hospital and medical.	9,772,749	0	0	0	0	0	0	0	9,772,749	0	0	0	0	xxx
Incentive pool, withhold adjustments and bonus amounts	3,738,435								3,738,435					XXX
15. Subtotal (Lines 8 to 14)	1.273.661.084	0	0	0	0	0	0	0	1,273,661,084	0	0	0	n	XXX
16. Net reinsurance recoveries	0								1,270,001,001					XXX
17. Total hospital and medical (Lines 15 minus 16)	1,273,661,084	n	0	0	0	Λ	0	0	1,273,661,084	0	n	0	n	XXX
18. Non-health claims (net)	1,270,001,004	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
Claims adjustment expenses including														
\$22,194,123 cost containment expenses	39,957,822								39.957.822				39.957.822	
20. General administrative expenses	174,301,270								174,222,642					
21. Increase in reserves for accident and health contracts	22,385,341								22,385,341					xxx
22. Increase in reserves for life contracts.	0	xxx	XXX	XXX	XXX	XXX	XXX	xxx	xxx	XXX	xxx	XXX	xxx	
23. Total underwriting deductions (Lines 17 to 22)	1,510,305,517	0	0	0	0	0	0	0	1,510,226,889	0	0	0	0	78,628
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	48,681,534	0	0	0	0	0	0	0	48,681,534	0	0	0	0	0
DETAILS OF WRITE-INS														
0501.														XXX
0502.														xxx
0503.														xxx
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	L0	0	0	0	0	XXX
0599. Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0601. Administrative Service Revenue	78.628	XXX	XXX	XXX	XXX	XXX	XXX	xxx	XXX	XXX	XXX	XXX	XXX	78.628
0602.		XXX	XXX	XXX	XXX	XXX	XXX	xxx	XXX	XXX	XXX	XXX	XXX	
0603.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698. Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	xxx	XXX	XXX	XXX	XXX	XXX	n
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	78.628	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	78.628
1301. Alternative Medical Cost	4,656,402	7551	,,,,,	,,,,,	7001	,,,,,	,,,,,	1 7001	4,656,402	,,,,,	7001	,,,,,	7,001	XXX
1302. Consumer Incentives	285,539								285,539					xxx
1303. PCMH Passthrough Expense.	3,179,558						1	1	3,179,558				1	XXX
1398. Summary of remaining write-ins for Line 13 from overflow page	1,651,250	0	n	n	n	n	n	n	1,651,250	n	0	n	n	XXX
1399. Totals (Lines 1301 through 1303 plus 1398) (Line 13 above)	9,772,749	0	0 n	n	n	n	n	0			n	0		XXX

\sim

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Blue Cross Complete of Michigan LLC

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

PART 1 - PREMIUMS				
Line of Business	1 Direct Business	2 Reinsurance Assumed	3 Reinsurance Ceded	4 Net Premium Income (Cols. 1+2-3)
Comprehensive (hospital and medical) individual				0
Comprehensive (hospital and medical) group				0
3. Medicare Supplement				0
4. Vision only				C
5. Dental only				0
6. Federal Employees Health Benefits Plan				0
7. Title XVIII - Medicare				
8. Title XIX – Medicaid	1,558,908,423			1 , 558 , 908 , 423
9. Credit A&H				C
10. Disability Income				
11. Long-Term Care				C
12. Other health				0
13. Health subtotal (Lines 1 through 12)		0	0	1,558,908,423
14. Life				C
15. Property/casualty				
16. Totals (Lines 13 to 15)	1,558,908,423	0	0	1,558,908,423

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 – CLAIMS INCURRED DURING THE YEAR

				PART 2 - 0	CLAIMS IN	CURRED DI	JRING THE	YEAR						
	1	Comprehensi Med		4	5	6	7	8	9	10	11	12	13	14
	Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non- Health
1. Payments during the year:					•									
1.1 Direct	1,274,958,497								1,274,958,497					
1.2 Reinsurance assumed	0											ļ		
1.3 Reinsurance ceded	0													
1.4 Net	1 ,274 ,958 ,497	0	0	0	0	0	0	0	,21 1,000,101	0	0	0	0	ļ0
Paid medical incentive pools and bonuses	3,738,538								3,738,538					
3. Claim liability December 31, current year from Part 2A:														
3.1 Direct	171,189,040	0	0	0	0	0	0	0	171,189,040	0	0	0	0	ļ0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	ļ0
3.4 Net	171,189,040	0	0	0	0	0	0	0	171,189,040	0	0	0	0	ļ0
 Claim reserve December 31, current year from Part 2D: 														
4.1 Direct	0													
4.2 Reinsurance assumed	0													
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	
4.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	
5. Accrued medical incentive pools and bonuses, current year	3,462,161								3,462,161					
6. Net healthcare receivables (a)	(535,687)								(535,687)					
7. Amounts recoverable from reinsurers December 31, current year	0													
Claim liability December 31, prior year from Part 2A: 8.1 Direct	176,760,575	0	0	0	0	0	0	0	176,760,575	0	0	0	0	0
8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8.4 Net	176,760,575	0	0	n l	0	0	0	0	176,760,575	0	n	0	0	
9. Claim reserve December 31, prior year from Part 2D:	170,700,070						0							
9.1 Direct	1	0	0 n		0	0	0]0 n	0	0	0	0	0	ال
9.2 Reinsurance assumed	0	0	 0		 0	1	0	0	0	0 N	0	ļ0	I	l
9.3 Reinsurance ceded		0				0	U	0	0		0	0	0	L
9.4 Net	‡0	0	0	0	0	0	0	J0	0	0	L0	0	0	L
10. Accrued medical incentive pools and bonuses, prior year	3,462,264	0	0	0	0	0	0	0	3,462,264	0	0	0	0	
11. Amounts recoverable from reinsurers December 31, prior year	0	0	0	0	0	0	0	0	0	0	0	0	0	C
12. Incurred benefits:														
12.1 Direct	1,269,922,649	0	0	0	0	0	0	0	1,269,922,649	0	0	0	0	ļC
12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	ļ0
12.3 Reinsurance ceded	. 0	0	0	0	0	0	0	0	0	0	0	0	0	(
12.4 Net	1,269,922,649	0	0	0	0	0	0	0	1 1 - 1	0	0	0	0	(
13. Incurred medical incentive pools and bonuses	3,738,435	0	0	0	0	0	0	0	3,738,435	0	0	0	0	

⁽a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	4	Compre (Hospital ar		4	г		7	8		40	44	40	40	44
	1	(Hospital al	3	4	5	6	Federal	8	9	10	11	12	13	14
	Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
Reported in Process of Adjustment:														
1.1. Direct	61,584,688								61,584,688					
1.2. Reinsurance assumed	0													
1.3. Reinsurance ceded	0													
1.4. Net	61,584,688	0	0	0	0	0	0	0	61,584,688	0	0	0	0	ļ
2. Incurred but Unreported:														
2.1. Direct	109,604,352								109,604,352					
2.2. Reinsurance assumed	0													
2.3. Reinsurance ceded	0													
2.4. Net	109,604,352	0	0	0	0	0	0	0	109,604,352	0	0	0	0	
3. Amounts Withheld from Paid Claims and Capitations:														
3.1. Direct	0													
3.2. Reinsurance assumed	0													
3.3. Reinsurance ceded	0													
3.4. Net	0	0	0	0	0	0	0	0	0	0	0	0	0	
4. TOTALS:														
4.1. Direct	171,189,040	0	0	0	0	0	0	0	171, 189, 040	0	0	0	0	
4.2. Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	ļ
4.3. Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	ļ
4.4. Net	171.189.040	0	٥ ا	0	0	0		0	171.189.040	0	0	0		

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR-NET OF REINSURANCE

PART 2B - ANALYSIS OF CLAIMS UNPAID - PI		OF KEINSUKA		ve and Claim	5	6
	Claims Paid D	uring the Year		31 of Current Year	3	U
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred in Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Ente of Business	or Guiront Tour	Barring and Total	T Hot Tour	Burng the roar	(Coldinio 1 · O)	i ilor rour
Comprehensive (hospital and medical) individual					0	0
Comprehensive (hospital and medical) group					0	0
3. Medicare Supplement					0	0
4. Vision Only					0	0
5. Dental Only					0	0
6. Federal Employees Health Benefits Plan					0	0
7. Title XVIII - Medicare					0	0
8. Title XIX - Medicaid	136,572,038	1 , 143 , 095 , 819	2,325,577	168,863,463	138,897,615	176 , 760 , 575
9. Credit A&H					0	0
10. Disability Income					0	0
11. Long-Term Care					0	0
12. Other health					0	0
13. Health subtotal (Lines 1 to 12)	136,572,038	1,143,095,819	2,325,577	168,863,463	138,897,615	176 , 760 , 575
14. Healthcare receivables (a)		4,173,673			0	0
15. Other non-health					0	0
16. Medical incentive pools and bonus amounts	3,738,538			3,462,161	3,738,538	3,462,264
17. Totals (Lines 13-14+15+16)	140,310,576	1,138,922,146	2,325,577	172,325,624	142,636,153	180,222,839

(a) Excludes \$loans or advances to providers not yet expensed.

Pt 2C - Sn A - Paid Claims - Comp

Pt 2C - Sn A - Paid Claims - MS NONE

Pt 2C - Sn A - Paid Claims - DO NONE

Pt 2C - Sn A - Paid Claims - VO
NONE

Pt 2C - Sn A - Paid Claims - FE NONE

Pt 2C - Sn A - Paid Claims - XV

NONE

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XIX Medicaid

		Cur	mulative Net Amounts F	aid aid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	662,671	662,606	661,781	661,781	661,781
2. 2019	569,182	635,325	635,674	634,305	634,305
3. 2020	XXX	620,306	701,322	701,333	699,579
4. 2021	XXX	XXX	909, 193	1,035,050	1,035,880
5. 2022	XXX	XXX	ДХХХ	997,002	1,138,237
6. 2023	XXX	XXX	XXX	XXX	1,138,922

Section B - Incurred Health Claims - Title XIX Medicaid

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
Year in Which Losses Were Incurred	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	592,260	588,925	661,781	661,781	661,781
2. 2019	647 , 456	639,818	635,674	634,305	634,305
3. 2020	XXX	725,415	703,604	701,333	699,579
4. 2021	XXX	XXX	1,056,861	1,040,001	1,035,880
5. 2022	XXX	XXX	LXXX	1,172,274	1,140,563
6. 2023	XXX	XXX	XXX	XXX	1,311,248

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX Medicaid

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
					Adjustment				Claims	
Years in which			Claim Adjustment		Expense			Unpaid Claims	Adjustment	
Premiums were Earned and Claims			Expense	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payments	Payments	Percent	(Col. 2+3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2019	818,927	634,305	28,200	4.4	662,505	80.9			662,505	80.9
2. 2020	917,571	699,579	31,237	4.5	730,816	79.6			730,816	79.6
3. 2021	1,231,753	1,035,880	32,244	3.1	1,068,124	86.7			1,068,124	86.7
4. 2022	1,380,609	1, 138, 237	35,099	3.1	1, 173, 337	85.0	2,788		1, 176, 125	85.2
5. 2023	1,558,908	1,138,922	40,026	3.5	1,178,948	75.6	171,863	2,603	1,353,414	86.8

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

		Cur	nulative Net Amounts F	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	662,671	662,606	661,781	661,781	661,781
2. 2019	569,182	635,325	635,674	634,305	634,305
3. 2020	XXX	620,306	701,322	701,333	699,579
4. 2021	XXX	XXX	909, 193	1,035,050	1,035,880
5. 2022	XXX	XXX	XXX	997,002	1,138,237
6. 2023	XXX	XXX	XXX	XXX	1,138,922

Section B - Incurred Health Claims - Grand Total

		Sum of Cumulati	ive Net Amount Paid an	d Claim Liability,	
	Claim F	Reserve and Medical In	centive Pool and Bonus	ses Outstanding at End	of Year
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	592,260	588,925	661,781	661,781	661,781
2. 2019	647 , 456	639,818	635,674	634,305	634,305
3. 2020	XXX	725,415	703,604	701,333	699,579
4. 2021	LXXX	XXX	1,056,861	1,040,001	1,035,880
5. 2022	XXX	XXX	XXX	1,172,274	1,140,563
6. 2023	XXX	XXX	XXX	XXX	1,311,248

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
					Adjustment				Claims	
Years in which			Claim Adjustment		Expense			Unpaid Claims	Adjustment	
Premiums were Earned and Claims			Expense	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payments	Payments	Percent	(Col. 2+3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2019	818,927	634,305	28,200	4.4	662,505	80.9	0	0	662,505	80.9
2. 2020	917,571	699,579	31,237	4.5	730,816	79.6	0	0	730,816	79.6
3. 2021	1,231,753	1,035,880	32,244	3.1	1,068,124	86.7	0	0	1,068,124	86.7
4. 2022	1,380,609	1,138,237	35,099	3.1	1,173,337	85.0	2,788	0	1 , 176 , 125	85.2
5. 2023	1,558,908	1,138,922	40,026	3.5	1,178,948	75.6	171,863	2,603	1,353,414	86.8

Pt 2C - Sn B - Incurred Claims - Comp

Pt 2C - Sn B - Incurred Claims - MS NONE

Pt 2C - Sn B - Incurred Claims - DO NONE

Pt 2C - Sn B - Incurred Claims - VO NONE

Pt 2C - Sn B - Incurred Claims - FE NONE

Pt 2C - Sn B - Incurred Claims - XV NONE

Part 2C - Sn C - Claims Expense Ratio Co NONE

Part 2C - Sn C - Claims Expense Ratio MS NONE

Part 2C - Sn C - Claims Expense Ratio DO NONE

Part 2C - Sn C - Claims Expense Ratio VO

NONE

Part 2C - Sn C - Claims Expense Ratio FE NONE

Part 2C - Sn C - Claims Expense Ratio XV

NONE

UNDERWRITING AND INVESTMENT EXHIBIT

	PART 2D - A			E FOR AC	CIDENT AN	PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY											
	1		ehensive & Medical)	4	5	6	7	8	9	10	11	12	13				
		2	3	1			Federal Employees		-								
				Medicare			Health Benefits		Title XIX		Disability	Long-Term					
	Total	Individual	Group	Supplement	Vision Only	Dental Only	Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other				
Unearned premium reserves	0																
Additional policy reserves (a)	22,385,341								22,385,341								
Reserve for future contingent benefits	0																
Reserve for rate credits or experience rating refunds (including																	
\$ for investment income)	0																
Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	0	0	0	0	0				
6. Totals (gross)	22,385,341	0	0	0	0	0	0	0	22,385,341	0	0	0	0				
7. Reinsurance ceded	0					ļ											
8. Totals (Net) (Page 3, Line 4)	22,385,341	0	0	0	0	0	0	0	22,385,341	0	0	0	0				
Present value of amounts not yet due on claims	0																
10. Reserve for future contingent benefits	0																
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0				
12. Totals (gross)	0	0	0	0	0	0	0	0	0	0	0	0	0				
13. Reinsurance ceded	0																
14. Totals (Net) (Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0				
DETAILS OF WRITE-INS																	
0501.																	
0502.																	
0503.																	
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0				
0599. Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	0	0	0	0				
1101																	
1102.																	
1103.																	
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0				
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0				

(a) Includes \$22,385,341 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

		Claim Adjustm	ent Expenses	3	4	5
		1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$for occupancy of own building)	425,947	295,600	3 ,417 ,255		4,138,802
	Salaries, wages and other benefits		10,206,512	61,090,473		86,694,231
3.	Commissions (less \$ceded plus					
	\$assumed)	0	0	0		0
4.	Legal fees and expenses					
5.	Certifications and accreditation fees					
	Auditing, actuarial and other consulting services					
7.	Traveling expenses	113,567	39 , 102	314,715		467 , 384
8.	Marketing and advertising					
9.	Postage, express and telephone					
10.	Printing and office supplies					
11.	Occupancy, depreciation and amortization					
12.						
13.	Cost or depreciation of EDP equipment and software					
14.	Outsourced services including EDP, claims, and other services					
15.	Boards, bureaus and association fees					
16.	Insurance, except on real estate					
17.	·					
18.	Group service and administration fees			l .		
	Reimbursements by uninsured plans			i i		
19.						
20.	Reimbursements from fiscal intermediaries Real estate expenses					
21.						
22.	Real estate taxes	19,998	13,878	243,473		211,349
23.	Taxes, licenses and fees:					0
	23.1 State and local insurance taxes		0	0		
	23.2 State premium taxes	l l				
	23.3 Regulatory authority licenses and fees					
	23.4 Payroll taxes		588,065			
	23.5 Other (excluding federal income and real estate taxes)		0			48,243
24.	Investment expenses not included elsewhere		0		239,537	239,537
25.	Aggregate write-ins for expenses		173,638	1,304,829	0	1,774,419
26.	Total expenses incurred (Lines 1 to 25)		17,763,699	i i		(a)214,498,629
27.	Less expenses unpaid December 31, current year					4,894,639
28.	Add expenses unpaid December 31, prior year				0	
29.	Amounts receivable relating to uninsured plans, prior year	0	0	0	0	0
30.	Amounts receivable relating to uninsured plans, current year					0
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	22,274,860	17,750,725	174,129,810	239,537	214,394,932
DETAII	LS OF WRITE-INS					
2501.	Consulting	0	0	153,670		153,670
2502.	Miscellaneous Expenses	193,395	173,638	22,752		389,785
2503.	Administrative Services	0	0	440,440		440,440
2598.	Summary of remaining write-ins for Line 25 from overflow page	102,557	0	687,967	0	790,524
2599.	Totals (Line 2501 through 2503 plus 2598) (Line 25 above)	295,952	173,638	1,304,829	0	1,774,419

EXHIBIT OF NET INVESTMENT INCOME

		1 1	2
		Collected	Earned
		During Year	During Year
1.	U.S. Government bonds	(a)416,950	468,189
1.1	Bonds exempt from U.S. tax	(a)	
1.2	Other bonds (unaffiliated)	1 '	1,746,697
1.3	Bonds of affiliates	(a)0	
2.1	Preferred stocks (unaffiliated)		
	Preferred stocks of affiliates		
2.2	Common stocks (unaffiliated)		1.481.389
2.21	,	0	
3.	Mortgage loans	1	
4.	Real estate		
5.	Contract loans.	1 1	
6.	Cash, cash equivalents and short-term investments		17,385,637
7.	Derivative instruments		17,000,007
8.	Other invested assets	1 17	
9.	Aggregate write-ins for investment income		
10.	Total gross investment income	20,496,507	21,081,912
	*		
11.	Investment expenses		(g)239,537
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)
13.	Interest expense		
14.	Depreciation on real estate and other invested assets		
15.	Aggregate write-ins for deductions from investment income		
16.	Total deductions (Lines 11 through 15)		239,537
17	Net investment income (Line 10 minus Line 16)	1	20,842,375
DETAI	LS OF WRITE-INS		
0901.			
0902.			
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
	Totals (Lines 0901 through 0903 plus 0998) (Line 9 above)	0	0
1501.		•	
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		
1599.	Totals (Lines 1501 through 1503 plus 1598) (Line 15 above)		1 0
1088.	Totals (Lines 1501 tillought 1505 plus 1586) (Line 15 above)		
(a) Incl	udes \$	68 623 poid for goory	d interest on purchases
	udes \$		
	udes \$		
	udes \$		u interest on purchases.
	udes \$4,125,887 accrual of discount less \$		d interest on nurshasse
	udes \$.1,2/3,/10 paid for accrue	u interest on purchases.
		duding fodoral income toye	attributable to
(0)	udes \$investment expenses and \$investment taxes, licenses and fees, exc	adding rederal income taxes	s, attributable to
	regated and Separate Accounts.		
(11) INCI	udes \$	to	
(I) INCI	udes \$ depreciation on real estate and \$ depreciation on other invested asse	ets.	

EXHIBIT OF CAPITAL GAINS (LOSSES)

		• • • • • • • • • • • • • • • • • • • •		_ ,	- ,	
		1	2	3	4	5
		Realized Gain (Loss) On Sales or Maturity	Other Realized Adjustments	Total Realized Capital Gain (Loss) (Columns 1 + 2)	Change in Unrealized Capital Gain (Loss)	Change in Unrealized Foreign Exchange Capital Gain (Loss)
1.	U.S. Government bonds				5,922	
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	(52,015)		(52,015)		
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)			0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	721,297	0	721,297	3,098,037	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0		0
5.	Contract loans			0		
6.	Cash, cash equivalents and short-term investments.	1,083		1,083	0	0
7.	Derivative instruments			0		
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	(5,922)	0
10.	Total capital gains (losses)	679,632	0	679,632	3,098,037	0
DETAI	LS OF WRITE-INS					
0901.	Tips adjustment			0	(5,922)	
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9 above)	0	0	0	(5.922)	0

EXHIBIT OF NONADMITTED ASSETS

		1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1	Bonds (Schedule D)	Nonaumitted Assets 0	Nonadmitted Assets	(Col. 2 - Col. 1)
	Stocks (Schedule D):			
	2.1 Preferred stocks	0	0	0
	2.2 Common stocks	0	0	0
3.	Mortgage loans on real estate (Schedule B):			
	3.1 First liens	0	0	0
	3.2 Other than first liens			0
4.	Real estate (Schedule A):			
	4.1 Properties occupied by the company	0	0	0
	4.2 Properties held for the production of income			
	4.3 Properties held for sale			0
5.	Cash (Schedule E-Part 1), cash equivalents (Schedule E-Part 2) and			
	short-term investments (Schedule DA)	0	0	0
6	Contract loans			0
1	Derivatives (Schedule DB)			0
	Other invested assets (Schedule BA)			0
i	Receivables for securities			0
	Securities lending reinvested collateral assets (Schedule DL)			0
	Aggregate write-ins for invested assets			0
	Subtotals, cash and invested assets (Lines 1 to 11)			0
l	Title plants (for Title insurers only).			
	Investment income due and accrued			0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection		0	0
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			0
16.	15.3 Accrued retrospective premiums and contracts subject to redetermination Reinsurance:	0	0	0
	16.1 Amounts recoverable from reinsurers		0	0
	16.2 Funds held by or deposited with reinsured companies		0	0
		0	0	0
	Amounts receivable relating to uninsured plans		0	0
18.1	Current federal and foreign income tax recoverable and interest thereon	0	0	0
i	Net deferred tax asset		515,129	515,129
	Guaranty funds receivable or on deposit			0
	Electronic data processing equipment and software			0
21.	Furniture and equipment, including health care delivery assets	675,137	955,028	279,891
22.	Net adjustment in assets and liabilities due to foreign exchange rates	0	0	0
23.	Receivables from parent, subsidiaries and affiliates	45,336	0	(45, 336)
24.	Health care and other amounts receivable	1,091,966	902,844	(189, 122)
	Aggregate write-ins for other-than-invested assets		2,577,415	838,926
	Total assets excluding Separate Accounts, Segregated Accounts and			
	Protected Cell Accounts (Lines 12 to 25)	3,550,928	4,950,416	1,399,488
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0
l	Total (Lines 26 and 27)	3,550,928	4,950,416	1,399,488
	LS OF WRITE-INS	0,000,020	1,000,110	1,000,100
l				
i	Summary of remaining write-ins for Line 11 from overflow page	i		Λ
		0	0	۰
	Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)			04 047
	Prepaid Expenses.		820,171	31,917
	9		375,000	375,000
	Leasehold Improvement		1,330,726	432,009
	Summary of remaining write-ins for Line 25 from overflow page		51,518	0
2599.	Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	1,738,489	2,577,415	838,926

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

	<u> </u>		Total Members at End o			6
	1	2	3	4	5	Current Year
Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	Current Year	Member Months
Health Maintenance Organizations	349,588	354,758	362,702	350 , 414		4,222,630
Provider Service Organizations.	0					
Preferred Provider Organizations	0					
4. Point of Service	0					
5. Indemnity Only	0					
Aggregate write-ins for other lines of business	0	0	0	0	0	0
7. Total	349,588	354,758	362,702	350,414	330,174	4,222,630
DETAILS OF WRITE-INS						
0601.						
0602.						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

NOTES TO FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies and Going Concern

Accounting Practices
The financial statements of Blue Cross Complete of Michigan LLC, (the Company) are presented on the basis of accounting practices prescribed or permitted by the Michigan Department of Insurance and Financial Services (DIFS),

The Michigan DIFS recognizes only statutory accounting practices prescribed or permitted by the State of Michigan for determining and reporting the financial condition and results of operations of an insurance company, and for determining its solvency under the Michigan Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures Manual (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the State of Michigan. The State has adopted certain prescribed or permitted accounting practices that differ from those found in NAIC SAP. Specifically, the State requires maternity care receivables due from the Department of Community Health to be reported on the health care and other amounts receivable line on page 2 of the Annual Statement. In NAIC SAP, this receivable is reported on the uncollected premiums and agents' balances in the course of collection line. This reclass does not have any monetary effect on net income, surplus or risk based capital. Also, effective January 1, 2018 DIFS requires Passthrough funds to be presented net within general administrative expenses. In NAIC SAP, the Passthrough funds would be reflected gross in revenue and medical expense. This reclass does not have a monetary effect on net income and surplus, nor prevents a regulatory event with regards to risk based capital.

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of Michigan is shown below

Net Income	SSAP#	F/S Page	F/S Line#	2023	2022
(1) Blue Cross Complete of Michigan LLC state basis (Page 4, Line 32, Columns 2 & 3)				\$51,705,363	\$28,989,589
(2) State Prescribed Practices that are an increase/(decrease) from NAIC SAP	00	4	2,14,21	\$0	\$0
(3) State Permitted Practices that are an increase/(decrease) from NAIC SAP				\$0	\$0
(4) NAIC SAP (1-2-3=4)				\$51,705,3635	\$28,989,589
SURPLUS (5) Blue Cross Complete of Michigan LLC state basis (Page 3, Line 33, Columns 3 & 4) (6) State Prescribed Practices that are an increase/(decrease) from NAIC SAP				\$236,595,109	\$177,539,306
Maternity case receivables reported as health care receivables	00	2	15.1, 24	\$0	\$0
(7) State Permitted Practices that are an increase/(decrease) from NAIC SAP				\$0	\$0
(8) NAIC SAP (5-6-7=8)				\$236,595,109	\$177,539,306

Use of Estimates in the Preparation of the Financial Statements
The preparation of financial statements in conformity with accounting practices prescribed or permitted by the Michigan DIFS requires management to make estimates and assumptic affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

- Inting Policy
 Company uses the following accounting policies:
 Short-term investments are stated at amortized cost.
 Bonds and other debt instruments are stated at amortized cost or at values prescribed by the Michigan DIFS. Bonds with an NAIC designation of 3 through 6 are reported at the lower of amortized cost or fair value. The amortized cost of bonds is adjusted for amortization of premiums and accretion of discounts using the scientific-interest method. Realized investment gains and losses on the sale of investments are recognized on the specific-identification basis as of the trade date. Realized losses also include losses for fair value declines that are considered to be other than temporary. Interest income is recognized when earned.
 Common Stocks are stated at market value.
 Preferred Stock None
 Mortgage Loans None
 Loan-backed securities Loan-backed securities are stated at amortized cost or at values prescribed by the Michigan DIFS with a NAIC designation of 1 or 2 and NAIC designations of 3 through 6 are reported at the lower of amortized cost or fair value. An invested asset is considered impaired when its fair value declines below cost. Pursuant to Statutory.

- Mortgage Loans None
 Loan-backed securities Loan-backed securities are stated at amortized cost or at values prescribed by the Michigan DIFS with a NAIC designation of 1 or 2 and NAIC designations of 3 through 6 are reported at the lower of amortized cost or fair value. An invested asset is considered impaired when its fair value declines below cost. Pursuant to Statement of Statutory Accounting Principles (SSAP) No. 43R, Loan-backed and Structured Securities, a loan-backed security is other-than-temporarily impaired if the present value of future cash flows expected to be collected from the security is less than the amortized cost of the security or where the Company intends to sell or does not have the intent and ability to retain the investment in the loan-backed security for the time sufficient to recover the security's amortized cost basis.

 Investments in subsidiaries, controlled and affiliated (SCA) entities None
 Derivatives None

Investments in joint ventures, partnerships and limited liability companies – None
Derivatives – None
Anticipated investment income as a factor in premium deficiency calculation – None
Accrued Medical Expense/Unpaid Claim Adjustment Expense – Accrued medical expenses and unpaid claims adjustment expenses include medical expenses billed and not paid, an estimate for costs incurred but not reported (IBNR), and estimated costs to process these claims. To estimate the IBNR balance the Company uses the triangulation method. The triangulation method uses estimates of completion factors, which are then applied to the total paid claims net of coordination of benefits to date for each incurred month. This provides an estimate of the total projected incurred claims and total amount outstanding of claims incurred but not reported. Consideration is also given to changes in turnaround time and claims processing, which may impact completion factors. Substantially all of the IBNR balance as of December 31, 2023 relates to the current year.

The Company determines IBNR in accordance with actuarial principles and assumptions that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the liabilities be adequate under moderately adverse circumstances. Actuarial estimates are based upon authorized healthcare services, past claims payment experience, member census, and other relevant factors. The Company consistently applies its reserving methodology from period to period and periodically reviews actual and anticipated experience compared to the assumptions used to establish medical costs.

While the Company believes the accrual for medical expenses is adequate, actual results could differ from such estimates. The Company recognizes any change in estimates in medical and hospital expenses in the period in which the change is identified.

- Fixed asset capitalization policy modifications Furniture and leasehold improvements are designated as "non-admitted assets" and are charged directly to capital and surplus. Depreciation is calculated on a straight-line basis over the estimated useful life of the assets, which ranges from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations when incurred. Pharmaceutical Rebates Estimated rebates to be collected are based on rebates invoiced to the pharmaceutical manufacturers.
- 13
- Going Concern None D.

2. Accounting Changes and Corrections of Errors - None

- 3. Business Combinations and Goodwill

 A. Statutory Purchase Method None
 B. Statutory Merger
 1. Name and brief description of the combined entities None
 2. Method of accounting None
 3. Shares of stock issued in the transaction None
 4. Details of results of operations None
 5. Adjustments recorded directly to surplus None
 C. Assumption Reinsurance None
 D. Impairment Loss recognized on Business Combinations and Goodwill None
 E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill None
- 4. Discontinued Operations
 - ued Operations
 Discontinued Operations Disposed of or Classified as Held for Sale None
 Change in Plan of Sale of Discontinued Operation None
 Nature of Any Significant Continuing Involvement with Discontinued Operations After Disposal None
 Equity Interest Retained in the Discontinued Operation After Disposal None

- B. C.
- Mortgage Loans, including Mezzanine Real Estate Loans None
 Debt Restructuring -None
 Reverse Mortgages None
 Loan-Backed Securities
 1. Prepayment assumptions None
 2. Recognized Other-than-Temporary Impairment None
 3. Present Value of Cash Flows None
 4. All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized:
 a. The aggregate amount of unrealized losses:
 - (1.) Less than 12 months (2.) 12 months or longer \$986
 - The aggregate related fair value of securities with unrealized losse
 - (1.) Less than 12 months \$3,308,886 (2.) 12 months or longer
- Dollar Repurchase Agreements and/or Securities Lending Transactions None Repurchase Agreements Transactions Accounted for as Secured Borrowing None Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing None Reverse Repurchase Agreements Transactions Accounted for as Sale None Reverse Repurchase Agreements Transactions Accounted for as a Sale None Reverse Repurchase Agreements Transactions Accounted for as a Sale None Reverse Repurchase Agreements Transactions Accounted for as a Sale None Low-income housing tax credits (LIHTC) None

Restricted Assets
1. Restricted Assets (Including Pledged)

	1	2	3	4	5	6	7
Restricted Asset Category	Total Gross (Admitted and Nonadmitted) Restricted From Current Year	Total Gross (Admitted and Nonadmitted) Restricted From Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Percentage Gross (Admitted & Nonadmitted) Restricted to Total Assets (a)	Percentage Admitted Restricted to Total Assets (b)
(a.) Subject to contractual obligation for which liability is not shown	\$ 0	\$ 0	\$ 0	\$ 0	\$ 0	— %	— %
(b) Collateral held under security lending agreements	0	0	0	0	0		I
(c) Subject to repurchase agreements	0	0	0	0	0		I
(d) Subject to reverse repurchase agreements	0	0	0	0	0	-	I
(e) Subject to dollar repurchase agreements	0	0	0	0	0		I
(f) Subject to dollar reverse repurchase agreements	0	0	0	0	0		-
(g) Placed under option contracts	0	0	0	0	0		l
(h) Letter stock or securities restricted as to sale – excluding FHLB capital stock	0	0	0	0	0		I
(i) FHLB capital stock	0	0	0	0	0		l
(j) On deposit with states	1,020,000	1,000,000	20,000	0	1,020,000	0.1	0.1
(k) On deposit with other regulatory bodies	0	0	0	0	0	_	_
(I) Pledged as collateral to FHLB (including assets backing funding agreements)	0	0	0	0	0		_
(m) Pledged as collateral not captured in other categories	0	0	0	0	0	_	_
(n) Other restricted assets	0	0	0	0	0	_	
(o) Total Restricted Assets	\$1,020,000	\$1,000,000	\$20,000	\$0	\$1,020,000	0.1 %	0.1 %

- Detail of Assets Pledged as Collateral Not Captured in Other Categories None
 Detail of Other Restricted Assets None
 Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements None Working Capital Finance Investments None
 Offsetting and Netting of Assets and Liabilities None
 Securities None
 Short Sales None
 Prepayment Penalty and Acceleration Fees None
 Reporting Entity's Share of Cash Pool by Asset Type None

- 6. Joint Ventures, Partnerships and Limited Liability Companies
 A. Investments in Joint Ventures, Partnerships or Limited Liability Companies that exceed 10% of admitted assets None
 B. Impaired investments in Joint Ventures, Partnerships and Limited Liability Companies None

- 7. Investment Income
 A. Due and accrued income is excluded from surplus on the following bases:
 All investment income due and accrued with amounts that are over 90 days past due.
 B. Total amount excluded was \$0.
 C. The gross, nonadmitted and admitted assets for interest income due and accrued.

\$ 995,571 Gross NonAdmitted \$ 995,571

The aggregate deferred interest.

Amount

Aggregate deferred interest \$0.00

The cumulative amounts of paid-in-kind (PIK) interest included in the current principle balance.

Amount Cumulative amounts of paid-in-kind (PIK) interest included in the current principle balance

- 8. Derivative Instruments
 A. Derivatives under SSAP No. 86 Derivatives None
 B. Derivatives under SSAP No. 108 Derivative Hedging Variable Annuity Guarantees
 1. Discussion of hedged item / hedging instruments and hedging strategy None
 2. Recognition of gains/losses and deferred assets and liabilities None
 3. Hedging Strategies Identified as No Longer Highly Effective None
 4. Hedging Strategies Terminated None

9. Income Taxes
In August 2022, the Inflation Reduction Act (the Act) was enacted into law, which included a new corporate alternative minimum tax (CAMT). The Act and CAMT are effective for tax years beginning after 2022. The Company is not subject to the CAMT.

A. The components of the net Deferred Tax Asset (DTA)/Deferred Tax Liability(DTL) are as follows:

(a)	Gross	DTA

- (b) Statutory Valuation Allowance Adjustments
- (c) Adjusted Gross DTA (1a 1b)
- (d) DTA Nonadmitted
- (e) Subtotal Net Admitted DTA (1c -1d)
- (f) DTL
- (g) Net Admitted DTA/(Net DTL) (1e 1f)

(a)	Gross DTA
(b)	Statutory Valuation Allowance Adjustments
(c)	Adjusted Gross DTA (1a - 1b)
(d)	DTA Nonadmitted

(e) Subtotal Net Admitted DTA (1c -1d) (f) DTL

(g) Net Admitted DTA/(Net DTL) (1e - 1f)

		12	2/31/2023		
	(1) Ordinary		(2)	(3)	
(Capital	(CoÌ 1+2) Total	
\$	6,039,907	\$	294,000	\$	6,333,907
	0		0		0
	6,039,907		294,000		6,333,907
	0		0		0
	6,039,907		294,000		6,333,907
	1,731,791		324,487		2,056,278
\$	4,308,116	\$	(30,487)	\$	4,277,629

	12	2/31/2022	
(4) Ordinary		(5) Capital	(6) (Col 4+5) Total
\$ 1,404,991	\$	662,101	\$ 2,067,092
0		0	0
1,404,991		662,101	2,067,092
0		515,129	 515,129
1,404,991		146,972	1,551,963
642,378		0	642,378
\$ 762,613	\$	146,972	\$ 909,585

						Cha				
			(7)			(3)	3)		/0-	(9) ol 7+8)
		Or	dina	ry		Cap	oital		(00	Total
(a)	Gross DTA	\$	4	1,634,916	\$		(368,101)	\$		4,266,815
(b)	Statutory Valuation Allowance Adjustments			0			0			0
(c)	Adjusted Gross DTA (1a - 1b)			1,634,916			(368,101)			4,266,815
(d)	DTA Nonadmitted			0			(515,129)			(515,129)
(e)	Subtotal Net Admitted DTA (1c -1d)			1,634,916			147,028			4,781,944
(f)	DTL			1,089,413			324,487			1,413,900
(g)	Net Admitted DTA/(Net DTL) (1e - 1f)	\$	- (3,545,503	\$		(177,459)	\$		3,368,044
Adm	ission Calculation Components SSAP No. 101:									
		[12/31/2023			
				(1)			(2)			(3) Col 1+2)
				Ordinary			Capital		((Col 1+2) Total
(a)	Federal Income Taxes paid in Prior Years Recoverable Through Loss Carrybacks		\$		3,866	\$	84,000) \$		5,627,866
(b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2	(a) above)	ľ							,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below))			0		42,000)		42,000
	(1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date				0		42,000)		42,000
	(2) Adjusted Gross DTA Allowed per Limitation Threshold				XXX		XXX	X		34,847,622
(c)	Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off	set by								
(-D	Gross DTL			49	6,041		168,000			664,041
	DTA Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)).		\$	6.03	9,907	\$	294,000) \$		6,333,907
			_	-,	-,					-,,
		[12/31/2022			
				(4)			(5)			(6) Col 4+5)
				Ordinary			Capital		((Col 4+5) Total
(a)	Federal Income Taxes paid in Prior Years Recoverable Through Loss Carrybacks		\$	78	3,585	\$	84,000) \$		867,585
(b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2	(a) above)								
	After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below)				0		42,000)		42,000
	(1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date				0		42,000)		42,000
	(2) Adjusted Gross DTA Allowed per Limitation Threshold				XXX		XXX	X		26,494,458
(c)	Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Officers DTI	set by		00	4 400		00.070	,		0.40.070
(d)	Gross DTL DTA Admitted as the result of application of SSAP No. 101.			62	1,406		20,972	<u> </u>		642,378
. ,	Total (2(a) + 2(b) + 2(c))		\$	1,40	4,991	\$	146,972	2 \$		1,551,963
		,	=							
							Change			
				(7)			(8)			(9) Col 7+8)
									()	
				Ordinary			Capital			Total
(a)	Federal Income Taxes paid in Prior Years Recoverable Through Loss Carrybacks		\$		0,281	\$	Capital 0) \$		Total 4,760,281
. ,	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2	` '	\$			\$	0			Total 4,760,281
. ,	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below))	\$		0	\$	0)		Total 4,760,281 0
. ,	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following)	69		0	\$	0)		Total 4,760,281 0 0
. ,	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold.)	\$		0	\$	0)		Total 4,760,281 0
(b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following)	\$	4,76	0 0 XXX	\$	0)) X		Total 4,760,281 0 0
(b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold)	\$	4,76	0	\$	0 0 0 XXX)) X		70tal 4,760,281 0 0 8,353,164
(b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off Gross DTL)	69 69	4,76	0 0 XXX	\$	0 0 0 XXX)) X	3	70tal 4,760,281 0 0 8,353,164
(b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below; (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off Gross DTL DTA Admitted as the result of application of SSAP No. 101.)		4,76	0 0 XXX (5,365)		0 0 0 XX; 147,028 147,028)) X	3	Total 4,760,281 0 0 8,353,164 21,663
(b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below; (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off Gross DTL DTA Admitted as the result of application of SSAP No. 101.)		4,76	0 0 XXX (5,365)		0 0 XXX 147,028)) X	3	Total 4,760,281 0 0 8,353,164 21,663
(b) (c) (d)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below; (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off Gross DTL DTA Admitted as the result of application of SSAP No. 101.	set by	\$	4,76	0 0 XXX 5,365)		0 0 0 XX; 147,028 147,028))) × 3 3 \$	3	Total 4,760,281 0 0 8,353,164 21,663 4,781,944
(b) (c) (d)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off. Gross DTL DTA Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	set by	\$	(12	0 0 XXX 5,365) 4,916	\$	147,028 2023 484)) × 3 3 \$		Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 %
(b) (c) (d)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off Gross DTL DTA Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	set by	\$	(12	0 0 XXX 5,365) 4,916	\$	0 0 0 XXX 147,028 147,028)) × 3 3 \$		Total 4,760,281 0 0 8,353,164 21,663 4,781,944
(b) (c) (d) (d) (b) a	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off Gross DTL DTA Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	set by	\$	(12	0 0 XXX 5,365) 4,916	\$	147,028 2023 484)) × 3 3 \$		Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 %
(b) (c) (d) (a) (b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by	\$	(12	0 0 XXX 5,365) 4,916	\$	00 00 00 00 147,028 147,028 2023 484 232,317,480	x x x =	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 %
(b) (c) (d) (a) (b) Impa	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off. Gross DTL DTA Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)). Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Am Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Tax Planning Strategies	set by	\$	(12	0 0 XXX 5,365) 4,916	\$	00 00 00 00 147,028 147,028 2023 484 232,317,480)) × 3 3 \$	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721
(b) (c) (d) (a) (b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off. Gross DTL DTA Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)). Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Am Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Tax Planning Strategies	set by	\$	(12	0 0 XXX 5,365) 4,916	\$	00 00 00 00 147,028 147,028 2023 484 232,317,480	x x x =	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 %
(b) (c) (d) (b)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off. Gross DTL DTA Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)). Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Am Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Tax Planning Strategies	set by nount. Percentage	\$ mitat	4,76 (12 4,63	0 0 XXX (5,5,365) 4,916	\$	00 00 00 00 147,028 147,028 2023 484 232,317,480))))XX X 3 \$ \$	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721
(b) (c) (d) (d) (a) (h) (a) (1)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below; (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold. Adjusted Gross DTA (Excluding The Amount Of DTA From 2(a) and 2(b) above) Off Gross DTL DTA Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Am Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation Am Amount Of Adjusted Gross DTA and Net Admitted DTA, By Tax Character As A is determination Of Adjusted Gross DTA and Net Admitted DTA, By Tax Character As A is determination Of Adjusted Gross DTA and Net Admitted DTA, By Tax Character As A is determination.	set by nount	\$	4,76 (12 4,63 ion In 2(b)2	0 0 XXX 55,365) 4,916	\$	00 00 00 00 147,028 147,028 2023 484 232,317,480))))XX X 3 \$ \$	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721
(b) (c) (d) (a) (b) (a) D (1) // (2) I	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by nount Threshold Lir Percentage	\$ mitat	4,76 (12 4,63 ion In 2(b)2	0 0 XXX 5,365) 4,916	\$	00 00 00 00 147,028 147,028 2023 484 232,317,480)))) X 3	\$ 1 /2023	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721
(b) (c) (d) (d) (a) D (1) / (2) I (3) I (3) I	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by nount Threshold Lir Percentage	\$ mitat	4,76 (12 4,63	0 0 0 XXX (5,5,365) 44,916	\$	147,028 147,028 2023 484 232,317,480)))) X 3	\$ 1 /2023	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000
(b) (c) (d) (d) (a) (b) (1) A (2) I (3) I	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by nount Threshold Lir Percentage	\$ mitat	4,76 (12 4,63	0 0 0 XXX (5,5,365) 44,916	\$	2023 484 232,317,480 (1) \$ 6,039,9	% §	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000
(b) (c) (d) (d) (a) D (1) / (2) I (3) I (3) I	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by nount Threshold Lir Percentage	\$ mitat	4,76 (12 4,63	0 0 0 XXX (5,5,365) 44,916	\$	2023 484 232,317,480 (1) \$ 6,039,9)))) X 3	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000
(b) (c) (d) (d) (a) (b) (1) A (2) I (3) I	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by nount Threshold Lir Percentage	\$ mitat	4,76 (12 4,63	0 0 0 XXX (5,5,365) 44,916	\$	2023 484 232,317,480 (1) \$ 6,039,9	% §	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000
(b) (c) (d) (d) (a) (1) // (2) I (3) I (4) I	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by Forcentage planning stra of the impace	\$ mitat	4,76 (12 4,63 ion In 2(b)2	0 0 XXX (5,365) 4,916	\$ \$	2023 484 232,317,480 (1) \$ 6,039,9	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000
(b) (c) (d) (a) (b) (1) // (2) (1) // (2)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by nount	\$ mitat	4,76 (12 4,63 ion In 2(b)2	0 0 0 XXX (5,5,365) 44,916	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	147,028 147,028 2023 484 232,317,480 (1) \$ 6,039,; \$ 6,039,;))))) X X 3 3 3 3 8 4 907 907	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000 294,000 (4) 662,101
(b) (c) (d) (d) (a) (a) D (1) / (2) I (3) I (2) I (3) I	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by Nount	\$ mitat	4,76 (12 4,63 ion In 2(b)2	0 0 0 XXX 4,916 4,916	\$ \$	00 00 00 00 00 00 00 00 00 00 00 00 00))))) X X 3 3 3 3 8 4 907 907	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000 294,000
(b) (c) (d) (d) (d) (1) (2) (3) (1) (2) (3) (3) (3) (4) (3) (4) (3) (4) (4) (5) (6) (6) (6) (6) (6) (6) (6) (6) (6) (6	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by Nount	\$ mitat	4,76 (12 4,63 ion In 2(b)2	0 0 0 XXX 4,916 4,916	\$ \$	147,028 147,028 2023 484 232,317,480 (1) \$ 6,039,; \$ 6,039,;))))) X X 3 3 3 3 8 4 907 907	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000 294,000 (4) 662,101
(b) (c) (d) (a) (b) (f) (a) D (1) (a) D (2) H (2) H (2) H (2) H (3) H (2) H (3) H	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by Nount	\$ mitat	4,76 (12 4,63 ion In 2(b)2	0 0 0 XXX 4,916 4,916	\$ \$	147,028 147,028 2023 484 232,317,480 (1) \$ 6,039,; \$ 6,039,;	% \$ 12/31/ 9907 12/31/ 9991	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000 294,000 (4) 662,101
(b) (c) (d) (a) (b) Impa (a) D (1) / (2) I (4) I (2) I (3)	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by Nount	\$ mitat	4,76 (12 4,63 ion In 2(b)2	0 0 0 XXX 4,916 4,916	\$ \$	147,028 147,028 2023 484 232,317,480 (1) \$ 6,039,9 \$ 6,039,9 \$ 1,404,9 \$ 1,404,9))))) X X 3 3 3 3 8 4 907 907	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000 294,000 (4) 662,101 146,972
(b) (c) (d) (a) (b) IImpa (a) D (1)/(2) I (3) I (4) I (2) I (3) I (4) I	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by Nount	\$ mitat	4,76 (12 4,63 ion In 2(b)2 es ax planning	0 0 0 XXX 4,916 4,916	\$ \$	147,028 147,028 2023 484 232,317,480 (1) \$ 6,039,3 \$ 6,039,3 \$ 1,404,3	12/31/ 12/31/ 907 907 Chai	\$ 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000 294,000 (4) 662,101 146,972
(b) (c) (d) (a) (b) Imparation (a) D (1)// (2) I (3) I (4) I (1)// (2) I (3) I (4) I	Adjusted Gross DTA Expected to be realized (Excluding the Amount of DTA From 2 After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 below, (1) Adjusted Gross DTA Expected to be Realized Following the Balance Sheet Date (2) Adjusted Gross DTA Allowed per Limitation Threshold	set by Nount	\$ mitat	4,76 (12 4,63 ion In 2(b)2 es ax planning es ax planning	0 0 XXX (5,5,365) 4,916	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	147,028 147,028 2023 484 232,317,480 (1) \$ 6,039,9 \$ 6,039,9 \$ 1,404,9 \$ 1,404,9	12/31/ 12/31/ 907 907 Chai	\$ 1	Total 4,760,281 0 0 8,353,164 21,663 4,781,944 2022 383 % 176,629,721 (2) 294,000 294,000 (4) 662,101 146,972

(b) Does the company's tax-planning strategies include the use of reinsurance? There are no temporary differences for which DTL are not recognized.

Yes ____

4,634,916 \$

No X

147,028

C. Current income taxes incurred consist of the following major components::

 Current 	Income	Tax
-----------------------------	--------	-----

		12/31/2023	12/31/2022	Change
(a)	Federal	\$ 18,355,162	\$ 7,676,235	\$ 10,678,927
(b)	Foreign	0	0	0
(c)	Subtotal	18,355,162	7,676,235	10,678,927
(d)	Federal income tax on net capital gains	143,016	243,818	(100,802)
(e)	Utilization of capital loss carry-forwards	0	0	0
(f)	Other	0	0	0
(g)	Federal and foreign income taxes incurred	\$ 18,498,178	\$ 7,920,053	\$ 10,578,125

2. DTA:

3.

DTA:			12/31/2023	12/31/2022	Change
(a) (Ordinary				
	(1) Discounting of unpaid losses	\$	593,290	\$ 552,330	\$ 40,960
	(2) Unearned premium reserve		0	0	(
	(3) Policyholder reserves		0	0	(
	(4) Investments		0	0	C
	(5) Deferred acquisition costs		0	0	C
	(6) Policyholder dividends accrual		0	0	C
	(7) Fixed assets		0	0	C
	(8) Compensation and benefits accrual		0	0	(
	(9) Premium Deficiency Reserve		4,700,922	0	4,700.922
	(10) Receivables – nonadmitted		745,695	852,661	(106,966
	(11) Net operating loss carry-forward		0	0	(100,000
	(12) Tax credit carry-forward		0	0	(
	(14) Other (including items <5% of total ordinary tax assets)		0	0	0
	(99) Subtotal		6,039,907	\$ 1,404,991	\$ 4,634,916
o) .	Statutory valuation allowance adjustment		0	0	C
c)	Nonadmitted		0	0	0
d) .	Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	\$	6,039,907	\$ 1,404,991	\$ 4,634,916
e) .	Capital:				
	(1) Investments	·····s	294,000	\$ 662,101	\$ (368,101
	(2) Net capital loss carry-forward		0	0	, ,
	(3) Real estate		0	0	
	(4) Other (including items <5% of total capital tax assets)		0	0	(
	(99) Subtotal	\$	294,000	\$ 	\$ (368,101
f)	Statutory valuation allowance adjustment		0	0	(
g) .	Nonadmitted		0	515,129	(515,129
h) .	Admitted capital DTA (2e99 - 2f - 2g)	\$	294,000	\$ 146,972	\$ 147,028
i)	Admitted DTA (2d + 2h)	\$	6,333,907	\$ 1,551,963	\$ 4,781,944
TL:					
(a)	Ordinary				
	(1) Investments	\$	0	\$ 0	\$ (
	(2) Fixed assets		330,509	480,009	(149,500
	(3) Deferred and uncollected premium (4) Policyholder reserves		0 1,221,769	0	1,221,769
	(5) Other (including items<5% of total ordinary tax liabilities)		179,513	162,369	17,14
	(99) Subtotal	\$	1,731,791	\$ 642,378	\$ 1,089,41
(b) (Capital				
	(1) Investments	\$	324,487	\$ 0	\$ 324,48
	(2) Real estate		0	0	(
	(3) Other (including items <5% of total capital tax liabilities) (99) Subtotal	\$	324,487	\$ 0	\$ 324,48
(0)			· · · · · · · · · · · · · · · · · · ·	 	
(C)	DTL (3a99 + 3b99)	\$	2,056,278	\$ 642,378	\$ 1,413,900

D. The Company's income tax incurred and change in deferred income tax differs from the amount obtained by applying federal statutory rate to income before income taxes as follows:

Current income tax expense incurred
Change in deferred income tax (without tax on unrealized gains and losses)
Total income tax expense reported
Income before taxes
Statutory Tax Rate
Expected income tax expense at statutory tax rate
Increase (decrease) in actual tax reported resulting from:
Permanent adjustments
Change in deferred taxes on nonadmitted assets

4. Net deferred tax assets/liabilities (2i - 3c)

Total income tax expense reported

12/31/2023	12/31/2022
18,498,178	7,920,053
(3,503,503)	 (39,660)
\$ 14,994,675	\$ 7,880,393
70,203,541	36,909,642
21%	21%
\$ 14,742,744	\$7,751,025
58,940	(64,541)
148,966	\$156,505
44,025	 \$37,404
\$ 14,994,675	\$7,880,393

26.3

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE BLUE CROSS COMPLETE OF MICHIGAN LLC

Operating loss carry-forward

1. As of December 31, 2020 there was \$0 net operating loss carryforward available for tax purposes..

2. The amount of Federal income taxes incurred that are available for recoupment in the event of future net losses are:

Ordinary Capital 2023 7,676,235

3. The aggregate amount of deposits admitted under Section 6603 of the Internal Revenue Code – None The Company is not included in a consolidated federal income tax return with its parent company., Federal or foreign income tax loss contingencies – None Repatriation Transition Tax (RTT) – None Alternative Minimum Tax (AMT) Credit – None

Blue Cross Blue Shield of Michigan, Inc. (BCBSM) \$

ion Concerning Parent, Subsidiaries, Affiliates and Other Related Parties
Material related party transactions – None
Transactions with related parties who are not reported on Schedule Y – None
At December 31, 2023, the Company reported the below amounts due to/(from) related parties:

1. ACS
\$ 13,996,800 PerformRx 1,218,281

E.

3. Blue Cross Blue Shield of Michigan, Inc. (BCBSM) \$ 0

Material management or service arrangements:

1. The Company maintains a Management and Administrative Services Agreement with ACS, an affiliated company.

2. PerformRx, a wholly owned subsidiary of AmeriHealth Caritas Health Plan (ACHP), provides pharmacy benefit management (PBM) services to the Company.

3. PerformSpecialty, a wholly owned subsidiary of PerformRx, supplies specialty pharmacy drugs to the Company. Amounts due to PerformSpecialty are included in claims unpaid on pg. 3 of the annual statement.

4. ACS furnishes to the Company employees necessary to carry out the business operations of the Company.

5. Blue Cross Blue Shield of Michigan (BCBSM) and its subsidiary provided the Company with certain administrative and medical services.

Parental guarantees – None

The Company is a joint venture formed by ACHP and MMH, each holding a 50% ownership interest. MMH is a wholly owned subsidiary of BCBSM. BCBSM indirectly holds a 38.74% ownership interest in ACHP, resulting in a 69.37% combined ownership in the Company.

Amounts deducted from the value of an upstream intermediate entity or ultimate parent owned, either directly or indirectly, via a downstream SCA entity – None Investments in an SCA entity that exceed 10% of admitted assets – None

Write-downs for impaired investments in SCA entities – None

Investments in a downstream noninsurance holding company – None

All SCA Investments

1. Balance Sheet Value (Admitted and Nonadmitted) All SCAs – None

NAIC filing response information – None

Investment in Insurance SCAs – None

NAIC filing response information – None

Investment in Insurance SCAs – None F. G.

L. M.

N. O.

11. Debt

Capital Notes – None Federal Home Loan Bank (FHLB) Agreements – None

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans
A. Defined Benefit Plan – None

B. C. D.

Defined Benefit Plan – None
Postretirement Plan Assets – None
Basis used to determine the overall expected long-term rate-of-return-on-assets assumption – None
Defined Contribution Plans – None
Multiemployer Plans – None
Consolidated/Holding Company Plans – None
Postemployment Benefits and Compensated Absences – None
Impact of Medicare Modernization Act on Postretirement Benefits – None

13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

A. Common Capital stock outstanding - None
Preferred stock - None
C. Dividend restrictions - Pursuant to Michigan Statute 500,1343, shareholder dividends shall be declared or paid only from earned surplus (excluding surplus arising from unrealized capital gains or a revaluation of assets), unless the commissioner approves the dividend prior to payment. Shareholder dividends declared by domestic insurers must be reported to the commissioner within 5 business days of the insurer declaring the dividend and at least 10 business days beginning from the date of receipt by the commissioner before the payment. Extraordinary dividends exceeding 10% of the insurer's prior year surplus or net gains from operations, excluding realized capital gains, of the preceding year, shall not be paid until 30 days after the commissioner has received notice of hte declaration and has not disapproved or has approved the payment within that period.

D. Dates and amounts of dividends paid - None
E. Stockholder's portion of ordinary dividend from profits - None
G. The total amount of advances to surplus not repaid - None
H. The amount of stock held by the Company for special purposes - None
Changes in balances of special surplus funds from the prior year - None
I. Changes in balances of special surplus funds from the prior year - None
I. Surplus notes - None
In pact of any restatement due to quasi-reorganization - None

Impact of any restatement due to quasi-reorganization – None Effective dates of all quasi-reorganizations in the prior 10 years is/are – None

Lessee Operating Leases
1. The Company leases office spaces under noncancelable operating lease agreements that expire between May 31, 2028, Rental expense for 2023 and 2022 was \$853,144 and \$824,969, respectively.
2. At December 31, 2023 the minimum aggregate rental commitments are as follow::

Year Ending December 31 2024 \$ 777.279 2025 796,512 2026 812 277 2027 814,172 2028 and therefore Total \$ 3.544,820

The company is not involved in any material sales - leaseback transactions.

В. С.

tion About Financial Instruments With Off-Balance-Sheet Risk And Financial Instruments With Concentrations of Credit Risk
The face, contract or notional principle amount – None
The nature and terms of the contract – None
The amount of accounting loss the entity would incur if any party to the financial instrument failed completely to perform according to the term of the contract and the collateral or other security, if any, for the amount due proved to be of no value to the entity – None
The Company's policy of requiring collateral or other security to support financial instruments subject to credit risk – None

D.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities
 A. Transfers of Receivables reported as Sales – None
 B. Transfer and Servicing of Financial Assets – None
 C. Wash Sales – None

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans
ASO Plans
The gains from operations from Administrative Services Only (ASO) uninsured plans and the uninsured portion of partially

Uninsured Portions of Partially ASO

1,148,136

1,148,136

(1) Net reimbursement for administrative expenses (including administrative fees) in excess of actual expenses Total net other income or expense (including interest paid to or received from plans) (3) Net gain or (loss) from operations (4) Total claim payment volume

ASC Plans – None Medicare or Other Similarly Structured Cost Based Reimbursement Contract – None 19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators – None

20. Fair Value Measurements A. B., Fair value measurement at reporting date 1. Certain assets and liabilities of the Company are measured and	d reported: (a) at amortize	d cost, or (b) at values	that approximate fair ve	alue due to their liquid o	or short-term nature
Fair Value Measurement at Reporting Date:			1	Net Asset Value	
Description for each class of asset or liability	Level 1	Level 2	Level 3	(NAV)	Total
a. Assets at fair value					
Common Stock					
Mutual funds	\$45,986,185	\$0	\$0	\$0	\$45,986,185
Money market mutual funds	\$0	\$0	\$0	\$0	\$0
Total Common Stock	\$45,986,185	\$0	\$0	\$0	\$45,986,185
Total assets at fair value	\$45,986,185	\$0	\$0	\$0	\$45,986,185
b. Liabilities at fair value					
Derivative liabilities	\$0	\$0	\$0	\$0	\$0
Total liabilities at fair value	\$0	\$0	\$0	\$0	\$0

- Fair Value Measurements in (Level 3) of the Fair Value Hierarchy None
 Transfers in and/or out of Level 3 None
 Fair value measurements categorized within Level 2 and 3 None
 The aggregate fair value of all financial instruments and the level within the fair value hierarchy

The aggregate fair value of all financial instrumer	nts and the level within th	e fair value nierarch	У				
						Net Asset Value	Not Practical
Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	Level 1	Level 2	Level 3	(NAV)	(Carrying
Common Stock	\$45,986,185	\$45,986,185	\$45.986.185	0.0	\$0	60	60

- Not Practicable to Estimate Fair Value None Investment measured using the NAV practical expedient None

21. Other Items

- Unusual or Infrequent Items None
 Unusual or Infrequent Items None
 Unusual or Infrequent Items None
 Other Disclosures None
 Other Disclosures None
 Business Interruption Insurance Recoveries None
 State Transferable and Non-transferable Tax Credits None
 State Transferable and Non-transferable Tax Credits None
 Subprime-Mortgage-Related Risk Exposure None
 Retained Assets None
 Insurance-Linked Securities (ILS) Contracts None
 Amounts that could be realized on Life Insurance where the reporting entity is owner and beneficiary or has otherwise obtained rights to control the policy None

22. Events SubsequentType 1 – Recognized subsequent events – None

Type 2 – Nonrecognized subsequent events
In March 2020, at the start of the COVID-19 pandemic, the U.S. federal government enacted the Families First Coronavirus Response Act, which included a requirement that state Medicaid programs keep their members continuously enrolled throughout the duration of the Public Health Emergency (PHE), creating a backlog in the Medicaid eligibility redetermination process. The Consolidated Appropriations Act of 2023 (CAA), which was signed into law on December 29, 2022, allowed states to resume member eligibility redetermination activities effective April 1, 2023 with a processing deadline to complete all cases by May 31, 2024. Additionally, the CAA called for the sunset of the enhanced Federal Medical Assistance Percentage provided to states during the pause in redeterminations effective December 31, 2023. Recently, the Centers for Medicare and Medicaid Services (CMS) extended certain time-limited flexibilities available to states to facilitate the Medicaid renewal process and published an interim final rule with comment period implementing reporting requirements and enforcement authorities. States that fail to comply with regulatory requirements may be required to submit a corrective action plan, suspend procedural disenrollments or receive civil monetary penalties among other actions. It remains unclear how these developments will impact Medicaid spend or enrollment or if they will lead to an extension of the May 31, 2024 processing deadline. The Company continues to closely monitor evolving developments related to the unwinding of the PHE and any potential corresponding impacts on the Company's financial condition, results of operations and cash flows.

On January 31, 2024, a series of restructuring transactions occurred, including the distribution of ACHP's 50% ownership interest in the Company to ACHP's ultimate parents, BCBSM and IBC MH LLC (IBC), in amounts proportional to their respective ownership interests in ACHP. As a result of these transactions, effective as of the transaction date, MMH holds a 69.37% ownership interest in the Company, with the remaining 30.63% ownership interest held by IBC. IBC is an indirect wholly owned subsidiary of Independence Health Group.

- 23. Reinsurance
 A. Ceded Reinsurance Report None
 B. Uncollectible Reinsurance None
 C. Commutation of Ceded Reinsurance None
 D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation
 1. Reporting Entity Ceding to Certified Reinsurer Whose Rating Was Downgraded or Status Subject to Revocation None
 2. Reporting Entity's Certified Reinsurer Rating Downgraded or Status Subject to Revocation None
 E. Reinsurance Credit None

- 24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

 A. Accrued retrospective premium adjustments None

 B. Accrued retrospective premium as an adjustment to earned premium None

 C. The amount of net premium written that are subject to retrospective rating features None

 D. Medical loss ratio rebates required pursuant to the Public Health Service Act None

 E. Risk-Sharing Provisions of the ACA None

25. Change in Incurred Claims and Claim Adjustment Expenses
Reserves as of December 31, 2022 were \$182,893,904 for incurred claims and claim adjustment expenses. As of December 31, 2023 \$142,981,641 has been paid for incurred claims and claim adjustment expenses at firbulable to insured events of prior years. Reserves remaining for prior years are now \$2,325,577 as a result of the re-estimation of unpaid claims and claim adjustment expenses. Therefore, there has been favorable prior year development of \$37,586,686 during 2023 for the year ended December 31, 2022 The favorable reserves developments are attributable to claims settled for amounts less than originally estimated, primarily due to lower health care cost trends as well as the actual claim submission time being faster than assumed in establishing the accrued medical expenses in the prior year. These adjustments are generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased as additional information becomes known regarding individual claims.

26. Intercompany Pooling Arrangements - None

27.Structured Settlements - None

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables – As discussed in note 10, PerformRx provides PBM services to the Company. PerformRx maintains the contractual arrangements with the drug manufacturers for rebates that cover the Company's membership. The Company receives those rebates collected by PerformRx relating to the Company's membership on a quarterly basis pursuant to the agreement. In accordance with SSAP No. 84, Health Care and Government Insured Plan Receivables, pharmacy rebate receivable of \$606,280 and \$387,557 at December 31, 2023 and 2022, respectively, were nonadmitted.

Quarter ended	Estimated pharmacy rebates as reported on financial statements	Pharmacy rebates as billed or otherwise confirmed	Actual rebates received within 90 days of billing	Actual rebates received within 91 to 180 days of billing	Actual rebates received more than 180 days after billing
12/31/2023	\$ 679,152	\$ 681,743	\$ 0	\$ 0	\$ 0
09/30/2023	\$ 585,000	\$ 722,903	\$ 0	\$ 0	\$ 0
06/30/2023	\$ 545,000	\$ 618,896	\$ 0	\$ 620,163	\$ 0
03/31/2023	\$ 545,000	\$ 584,699	\$ 0	\$ 582,073	\$ 0
12/31/2022	\$ 484,604	\$ 544,722	\$ 0	\$ 545,207	\$ 0
09/30/2022	\$ 448,000	\$ 479,193	\$ 0	\$ 490,234	\$ 0
06/30/2022	\$ 428,000	\$ 449,384	\$ 0	\$ 460,964	\$ 202,065
03/31/2022	\$ 423,000	\$ 437,864	\$ 0	\$ 442,636	\$ 0
12/31/2021	\$ 439,385	\$ 436,373	\$ 0	\$ 442,016	\$ 0
09/30/2021	\$ 483,000	\$ 449,736	\$ 0	\$ 455,797	\$ 0
06/30/2021	\$ 508,000	\$ 485,983	\$ 410,068	\$ 0	\$ 81,860
03/31/2021	\$ 496,000	\$ 511,406	\$ 0	\$ 510,444	\$ 11,137

B. Risk Sharing Receivables - None

29. Participating Policies - None

30. Premium Deficiency Reserves

22,385,341

Premium Deficiency Reserves Date of the most recent evaluation of this liability

December 31, 2023 Was anticipated investment income utilized in the calculation? Yes _

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Blue Cross Complete of Michigan LLC GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES

GENERAL 1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of

1.1	which is an insurer? If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.	Yes [}	X] No []
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?] N/A [
1.3	State Regulating? Michigan	. , .	J N/A []
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?] No [X]
1.5 2.1	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group. Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?	Yes [] No [X]
2.2	, ,		12/21/2021
3.1	State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This		12/31/2021
3.3	date should be the date of the examined balance sheet and not the date the report was completed or released. State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or		12/31/2021
2.4			06/21/2023
3.4 3.5			
3.6	statement filed with Departments? Have all of the recommendations within the latest financial examination report been complied with? Yes] N/A [X]] N/A [X]
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity) receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business?	Yes [] No [X]
	4.12 renewals?	Yes [] No [X]
4.2	During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate, receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct programs of		
	direct premiums) of: 4.21 sales of new business?	Yes [] No [X]
5.1	4.22 renewals? Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?	Yes [Yes [] No [X]] No [X]
	If yes, complete and file the merger history data file with the NAIC. If yes, provide the name of the entity, NAIC company code, and state of domicile (use two letter state abbreviation) for any entity that has	, 55] []
5.2	ceased to exist as a result of the merger or consolidation.		
	1 2 3		
	Name of Entity NAIC Company Code State of Domicile		
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period?] No [X]
6.2	If yes, give full information	163 [] NO [X]
7.1 7.2	, 3 (- // ,) , , , , , , , , , , , , , , , ,	Yes [] No [X]
	7.21 State the percentage of foreign control 7.22 State the nationality(s) of the foreign person(s) or entity(s); or if the entity is a mutual or reciprocal, the nationality of its		0.0 %
	manager or attorney-in-fact and identify the type of entity(s) (e.g., individual, corporation, government, manager or attorney in-fact).		
	1 2		
	Nationality Type of Entity		
8.1 8.2	Is the company a subsidiary of a depository institution holding company (DIHC) or a DIHC itself, regulated by the Federal Reserve Board? If response to 8.1 is yes, please identify the name of the DIHC.	Yes [] No [X]
8.3	Is the company affiliated with one or more banks, thrifts or securities firms?	Yes [] No [X]
8.4	If response to 8.3 is yes, please provide the names and locations (city and state of the main office) of any affiliates regulated by a federal financial regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.	, 550	, []
	1 2 3 4 5	6	7
	Location Affiliate Name (City, State) FRB OCC FDIC	SEC	
8.5	Is the reporting entity a depository institution holding company with significant insurance operations as defined by the Board of Governors	Vos f	l Norvi
8.6	of Federal Reserve System or a subsidiary of the depository institution holding company? If response to 8.5 is no, is the reporting entity a company or subsidiary of a company that has otherwise been made subject	Yes [] No [X]
9.	to the Federal Reserve Board's capital rule? What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?] No []	X] N/A []
	Deloitte & Touche LLP 1700 Market Street, Suite 2700, Philadelphia, PA 19103. Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant		
۱۵.۱	requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation?	Yes [] No [X]
10.2	If the response to 10.1 is yes, provide information related to this exemption:	100 [1 110 [11]
10.3	Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation?	Yes [] No [X]

GENERAL INTERROGATORIES PART 1 - COMMON INTERROGATORIES

				PART 1 - COMMON	INTERROG	ATORIES						
10.4	If the	response to 10.3	is yes, provide inform	ation related to this exemption:								
			y established an Audit is no or n/a, please e	Committee in compliance with the cxplain	domiciliary state ir	nsurance laws?	Yes	[X] No]] N	/A []
11.	Jose	ulting firm) of the i eph Fedro, Direct	ndividual providing the or of Actuarial Service	e statement of actuarial opinion/certies, AmeriHealth Caritas Family of 0	ification? Companies, 3875	ry/consultant associated with an actu West Chester Pike, Newtown Square	, PA					
12.1			• .	of a real estate holding company or	otherwise hold re 12.11 Name of 12.12 Number of	al estate indirectly? real estate holding company of parcels involved						
12.2	If yes,	, provide explana	tion		12.13 Total boo	k/adjusted carrying value	\$					
				EN REPORTING ENTITIES ONLY: ear in the United States manager or	the United States	s trustees of the reporting entity?						
13.2	Does	this statement co	ontain all business trar	nsacted for the reporting entity through	gh its United State	es Branch on risks wherever located?		Yes	ſΧ	1	No [[]
13.3	Have	there been any o	hanges made to any o	of the trust indentures during the year	ar?		V	Yes				[X]
13.4 14.1		. , ,	•	or entry state approved the change officer, principal financial officer, principal financial officer, principal		officer or controller, or persons perfor	Yes ming	[] No	l] N	/A [.]
	simila a. Ho	ar functions) of th nest and ethical	e reporting entity subj	ect to a code of ethics, which include	es the following st			Yes	[X]	No [[]
	b. Ful			able disclosure in the periodic report	s required to be fi	iled by the reporting entity;						
1111	d. The	e prompt internal countability for ad	reporting of violations herence to the code.	laws, rules and regulations; to an appropriate person or persons	s identified in the	code; and						
			is no, please explain:					.,		,		
			for senior managers to is yes, provide inform	peen amended? ation related to amendment(s).				Yes	[]	No [[X]
			the code of ethics be is yes, provide the na	en waived for any of the specified of ture of any waiver(s).	fficers?			Yes	[]	No [[X]
15.1	Is the	reporting entity t	ne beneficiary of a Let	ter of Credit that is unrelated to rein	surance where the	e issuing or confirming bank is not on t	he					
	SVO I	Bank List? response to 15.1	is yes, indicate the Ar		Routing Number	and the name of the issuing or confirm		Yes	[]	No	[X]
			1	2		3	\top	4			1	
		1	nerican ankers									
		1	ociation Nouting	Issuing or Confirming								
		N N	umber	Bank Name		s That Can Trigger the Letter of Credit		Amoun		—	-	
				BOARD OF	DIRECTOR	S						
16.	Is the		e of all investments of			ard of directors or a subordinate comm	ittee	Vec	ſΧ	1	No 1	r 1
17.	Does	the reporting en	tity keep a complete	permanent record of the proceeding	gs of its board o	f directors and all subordinate commi	ttees		•	•		
18.		he reporting entit				ees of any material interest or affiliatio		Yes	[X]	No [[]
		art of any of its operson?	fficers, directors, trus	tees or responsible employees that	is in conflict or i	s likely to conflict with the official dution	es of	Yes	[X]	No [[]
10	Hac tl	his statement hee	an nrangrad using a ha	FINANCIAL asis of accounting other than Statuto	-	incinles (e.g. Generally Accented						
	Accou	unting Principles)	?	ū						•		[X]
20.1	Total	amount loaned d	uring the year (inclusiv	ve of Separate Accounts, exclusive of	of policy loans):	20.11 To directors or other officers 20.12 To stockholders not officers						
						20.13 Trustees, supreme or grand (Fraternal only)						
20.2			outstanding at the end	of year (inclusive of Separate Acco	unts, exclusive of	f .						
	policy	loans):				20.21 To directors or other officers 20.22 To stockholders not officers						
						20.23 Trustees, supreme or grand (Fraternal only)						
21.1				subject to a contractual obligation to	transfer to anothe	• • • • • • • • • • • • • • • • • • • •	Ψ					
21.2	•	• .	ed in the statement? t thereof at December	31 of the current year:	21.21 Rented fr	rom others	\$	Yes	-			[X]
				•	21.22 Borrowed	from others	\$					
					21.23 Leased fr 21.24 Other	rom others						
22.1		this statement in		sessments as described in the Annu		tructions other than guaranty fund or						[X]
22.2	•	wer is yes:	occomenta :			paid as losses or risk adjustment						
					22.22 Amount 22.23 Other an	paid as expenses nounts paid						
23.1	Does	the reporting ent	ity report any amounts	due from parent, subsidiaries or aff		·	Ψ					[X]
23.2 24.1	•	,		parent included in the Page 2 amou		the third neutre t	\$					
	full wi	thin 90 days?		gent commissions in which the amou				Yes	[]	No [[X]
24.2	If the	response to 24.1	is yes, identify the thin	rd-party that pays the agents and wh	nether they are a r	related party.	_					
			NI-	1 me of Third-Party	l	2 Party Agent a Related Party (Yes/No)						

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES

1 2 Name of Third-Party Is the Third-Party Agent a Related Party (Yes/N					
INVES	TMENT				

	INVESTMENT				
	Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in the actual possession of the reporting entity on said date? (other than securities lending programs addressed in 25.03). If no, give full and complete information, relating thereto	in	Yes [X] No	[]
25.03	For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, a whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)	ınd			
25.04	For the reporting entity's securities lending program, report amount of collateral for conforming programs as outlined in the Risk-Based Capital Instructions.				.0
25.05	For the reporting entity's securities lending program, report amount of collateral for other programs.				.0
25.06	Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract?	Yes [] No [] NA	[X]
	1 3 ,	Yes [] No [] NA	[X]
	3	Yes [] No [] NA	[X]
25.09	For the reporting entity's securities lending program, state the amount of the following as of December 31 of the current year: 25.091 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2				
	25.092 Total book/adjusted carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2				
00.4	25.093 Total payable for securities lending reported on the liability page	•			0
26.1 26.2	Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in for (Exclude securities subject to Interrogatory 24.1 and 25.03). If yes, state the amount thereof at December 31 of the current year:		Yes [1 [X	No [
	26.21 Subject to repurchase agreements	\$			
	26.22 Subject to reverse repurchase agreements				
	26.23 Subject to dollar repurchase agreements				
	26.24 Subject to reverse dollar repurchase agreements				
	26.25 Placed under option agreements 26.26 Letter stock or securities restricted as to sale – excluding FHLB Capital Stock				
	26.27 FHLB Capital Stock				
	26.28 On deposit with states				
	26.29 On deposit with other regulatory bodies				
	26.30 Pledged as collateral – excluding collateral pledged to an FHLB	\$			
	26.31 Pledged as collateral to FHLB – including assets backing funding agreements	\$			
	26.32 Other	\$			
26.3	For category (26.26) provide the following:				
	1 2 Nature of Restriction Description		3 Amount		
27.1					
	Does the reporting entity have any hedging transactions reported on Schedule DB?		Yes [] No	[X]
		Yes [Yes [] No [] No	
	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement.	Yes [
INES	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state?	Yes [] N/A	
INES 27.3	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. 2.27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize:	Yes [] No [] N/A	No [X
INES 27.3	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. 2.27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108	Yes [] No [Yes [] N/A	No [X
INES 27.3	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. 2.27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize:	Yes [] No [] N/A	No [X
INES 27.3	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. 2.27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108	Yes [] No [Yes [] N/A	No [X
INES 27.3 27.4	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. 227.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108 27.42 Permitted accounting practice 27.43 Other accounting guidance By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to	Yes [Yes [Yes [Yes [Yes [Yes [] N/A	No [X No [No [No [No [
INES 27.3 27.4	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. 3 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108 27.42 Permitted accounting practice 27.43 Other accounting guidance	Yes [] No [Yes [Yes [] N/A	No [X No [No [
INES 27.3 27.4	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108 27.42 Permitted accounting practice 27.43 Other accounting guidance By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following: • The reporting entity has obtained explicit approval from the domiciliary state.	f VM- t. fined	Yes [Yes [Yes [Yes [Yes [] N/A	No [X No [No [No [No [
INES 27.3 27.4 27.5	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. 3 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108 27.42 Permitted accounting practice 27.43 Other accounting guidance By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following: • The reporting entity has obtained explicit approval from the domiciliary state. • Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21. • Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of 21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount • Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly Defined Hedging Strategy is the hedging strategy being used by the cominits actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of	f VM- t. fined	Yes [Yes [Yes [Yes [Yes [] N/A	No [X No [No [No [No [
INES 27.3 27.4 27.5	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. S 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108 27.42 Permitted accounting practice 27.43 Other accounting guidance By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following: • The reporting entity has obtained explicit approval from the domiciliary state. • Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21. • Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment or 21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount • Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly De Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the com in its actual day-to-day risk mitigation efforts.	f VM- t. fined pany	Yes [Yes [Yes [Yes [Yes [] N/A	No [X No [No [No [No [
INES 27.3 27.4 27.5	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement. 3 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108 27.42 Permitted accounting practice 27.43 Other accounting guidance By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following: • The reporting entity has obtained explicit approval from the domiciliary state. • Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21. • Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of 21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount ended in the provides of the special accounting provisions is consistent with the hedging strategy meets the definition of a Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the coming its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity? If yes, state the amount thereof at December 31 of the current year.	f VM- t. fined pany	Yes [Yes [Yes [Yes [Yes [Yes [] N/A	No [X No [No [No [No [No [No [No

29.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1 2			
Name of Custodian(s)	Custodian's Address		
The Northern Trust Company	50 South La Salle Street, Chicago, Illinois 60603		

29.02 For all agreements that do not comply with the requirements of the NAIC *Financial Condition Examiners Handbook*, provide the name, location and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)
Question 29 answered "Yes"		

29.03 Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year? 29.04 If yes, give full and complete information relating thereto:

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Blue Cross Complete of Michigan LLC GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES

1	2	3	4
		Date of	
Old Custodian	New Custodian	Change	Reason
PNC Institutional Asset Management	The Northern Trust Company		Consolidation of accounts to one custodian, improved efficiencies, and additional capabilities

29.05 Investment management - Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
Pamela Schmidt, who makes recommendations to BOD	
Western Asset Management Company.	U
PNC Capital Advisors. LLC.	U

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") manage more than 10% of the reporting entity's invested assets?

Yes [X] No []

29.0598 For firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?

Yes [] No [X]

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
Central Registration	Name of Firm or	Legal Entity		Investment Management
Depository Number	Individual	Identifier (LEI)	Registered With	Agreement (IMA) Filed
	Western Asset Management			
CRD 110441	Company	549300C5A561UXU1CN46	SEC	NO
CRD 151829	PNC Capital Advisors, LLC	549300WVB7V48QCY3U49	SEC.	NO
	,			!

30.1 Does the reporting entity have any diversified mutual funds reported in Schedule D - Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5 (b) (1)])? 30.2 If yes, complete the following schedule:

Yes [X] No []

	1	2	3
	CUSIP#	Name of Mutual Fund	Book/Adjusted Carrying Value
30.2001	302933-50-2	FMI:LARGE CAP INST	6,638,459
30.2002 4	45775L -40 -8.	T ROWE PRICE LC GRO I	7,279,123
30.2003	693390-60-1	PIMCO:SHORT-TERM INST	32,068,603
			, ,
30.2999 T	TOTAL		45,986,185

30.3 For each mutual fund listed in the table above, complete the following schedule:

1 Name of Mutual Fund (from above table)	2 Name of Significant Holding of the Mutual Fund	3 Amount of Mutual Fund's Book/Adjusted Carrying Value Attributable to the Holding	4 Date of Valuation
FMI:LARGE CAP INST	Alphabet Inc Cl A	90,293,400	09/30/2023
FMI:LARGE CAP INST	Ferguson PLC	85,524,400	09/30/2023
FMI:LARGE CAP INST	Berkshire Hathaway Inc. CI B		09/30/2023
FMI:LARGE CAP INST	UnitedHealth Group Inc		09/30/2023
FMI:LARGE CAP INST	Avery Dennison Corp	73,981,350	09/30/2023
T ROWE PRICE LC GRO I	Microsoft	2,529,985,000	12/31/2023
T ROWE PRICE LC GRO I	Apple	1,639,537,000	12/31/2023
T ROWE PRICE LC GRO I	Amazon.com	1,394,983,000	12/31/2023
T ROWE PRICE LC GRO I	Alphabet, Class A	1,278,595,000	12/31/2023
T ROWE PRICE LC GRO I	NVIDIA	979,210,000	12/31/2023
PIMCO:SHORT-TERM INST	U.S. TREASURY BILLS 5.465%	1,897,644,000	09/30/2023
PIMCO:SHORT-TERM INST	Federal Home Loan Bank 5.500%	197 ,517 ,000	09/30/2023
PIMCO:SHORT-TERM INST	Freddie Mac 5.550%	180 ,775 ,000	09/30/2023
PIMCO:SHORT-TERM INST	Charter Communications Operating	170,370,000	09/30/2023
PIMCO:SHORT-TERM INST	Freddie Mac 5.680%	160,997,000	09/30/2023

Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or

stateme	nt value for fair value.			
		1	2	3
				Excess of Statement
				over Fair Value (-),
		Statement (Admitted)		or Fair Value
		Value	Fair Value	over Statement (+)
31.1	Bonds	133,808,951		984,146
31.2	Preferred Stocks	0		0
31.3	Totals	133,808,951	134,793,097	984,146

31.4 Describe the sources or methods utilized in determining the fair values.

Fair value is based on pricing as provided by custodian pricing. For short-term investments, cost approximates fair value due to the short term nature of these investments.

32.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?

32.2 If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?

32.3 If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:

Yes [X] No [] 33.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?

Yes [X] No []

Yes [X] No []

33.2 If no, list exceptions:

34. By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a.Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an

Yes [] No [X]

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES

FE or PL security is not available.

- b.Issuer or obligor is current on all contracted interest and principal payments.

 c.The insurer has an actual expectation of ultimate payment of all contracted interest and principal

	Has the reporting entity self-designated 5GI securities?					
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as an NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. Has the reporting entity self-designated PLGI securities?		Yes []	No [[X]
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?		Yes []	No [[X]
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliated then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a -37.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?	Yes [X]	No []	NA [:]
38.1	Does the reporting entity directly hold cryptocurrencies?		Yes [1	No [X]
	If the response to 38.1 is yes, on what schedule are they reported?			•	٠	,
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies?		Yes []	No [Х]
39.2	If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately converted to U.S. dollars?					

39.3 If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premiums or that are held directly.

	2	3
1	Immediately Converted to USD,	Accepted for Payment
Name of Cryptocurrency	Directly Held, or Both	of Premiums
	·	

Yes [] No [X] Yes [] No [X]

.0

OTHER

39.22 Immediately converted to U.S. dollars

- ..194 , 747 40.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?
- 40.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations, and statistical or rating bureaus during the period covered by this statement.

1	2
Name	Amount Paid
BCBS Association Dues.	\$194,747
	, ,

41.1 Amount of payments for legal expenses, if any?

.24,164

41.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1	2
Name	Amount Paid
BCBSM	\$24,164

- 42.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers, or departments of government, if any? \$
- 42.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers, or departments of government during the period covered by this statement.

1	2
Name	Amount Paid
	\$
	\$
	\$

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 1.2 1.3	Does the reporting entity have any direct Medicare Supp If yes, indicate premium earned on U.S. business only. What portion of Item (1.2) is not reported on the Medicar 1.31 Reason for excluding	e Supplement Insurance I	Experience Exhibit?	\$	Yes [] No [X]
1.4 1.5 1.6	Indicate amount of earned premium attributable to Canac Indicate total incurred claims on all Medicare Supplement Individual policies:		ot included in Item (1.2) above	·	0
1.5	Training policies.		Most current three years: 1.61 Total premium earned 1.62 Total incurred claims 1.63 Number of covered lives All years prior to most current thre 1.64 Total premium earned 1.65 Total incurred claims	\$ e years: \$ \$	
1.7	Group policies:		1.66 Number of covered lives		0
			Most current three years: 1.71 Total premium earned 1.72 Total incurred claims 1.73 Number of covered lives All years prior to most current thre 1.74 Total premium earned 1.75 Total incurred claims	\$ e years: \$ \$	
2.	Health Test:		1.76 Number of covered lives		0
	Tiodal Tool		1 Current Year	2 Prior Year	
	2.1 2.2 2.3 2.4 2.5 2.6	Premium Numerator Premium Denominator Premium Ratio (2.1/2.2) Reserve Numerator Reserve Denominator Reserve Ratio (2.4/2.5)	\$1,558,908,423 \$1,558,908,423	\$	8 0 9
3.1	Has the reporting entity received any endowment or g returned when, as and if the earnings of the reporting entity yes, give particulars:		tals, physicians, dentists, or other	s that is agreed will be	Yes [] No [X]
4.1 4.2 5.1 5.2	Have copies of all agreements stating the period and dependents been filed with the appropriate regulatory ag If not previously filed, furnish herewith a copy(ies) of such Does the reporting entity have stop-loss reinsurance? If no, explain: Blue Cross Complete of Michigan LLC is an established.	ency? h agreement(s). Do these	e agreements include additional ber		Yes [X] No [] Yes [] No [] Yes [] No [X]
5.3	Maximum retained risk (see instructions)	r Fiait with over 330,000 C	5.31 Comprehensive Medical 5.32 Medical Only 5.33 Medicare Supplement 5.34 Dental and Vision 5.35 Other Limited Benefit Plan 5.36 Other	\$ \$ \$	
6.	Describe arrangement which the reporting entity may including hold harmless provisions, conversion privilege any other agreements: All providers have executed hold-harmless agreements	s with other carriers, agre	pers and their dependents against ements with providers to continue	t the risk of insolvency	
7.1 7.2	Does the reporting entity set up its claim liability for provi If no, give details				Yes [X] No []
8.	Provide the following information regarding participating		per of providers at start of reporting	Vear	36,579
			er of providers at start of reporting er of providers at end of reporting y	•	47 ,957
9.1 9.2	Does the reporting entity have business subject to premi If yes, direct premium earned:	um rate guarantees?			Yes [] No [X]
			ess with rate guarantees between 1 ess with rate guarantees over 36 mo		

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

10.1 Does the reporting entity have Incentive Pool, \	Nithhold or Bonus Arrangements in its provider contracts?	Yes [X] No []
10.2 If yes:		
	10.21 Maximum amount payable bonuses	\$3,000,000
	10.22 Amount actually paid for year bonuses	\$3,738,538
	10.23 Maximum amount payable withholds	\$
	10.24 Amount actually paid for year withholds	\$
11.1 Is the reporting entity organized as:		
	11.12 A Medical Group/Staff Model,	Yes [] No [X]
	11.13 An Individual Practice Association (IPA), or,	Yes [X] No []
	11.14 A Mixed Model (combination of above)?	Yes [] No [X]
11.2 Is the reporting entity subject to Statutory Minin	num Capital and Surplus Requirements?	Yes [X] No []
11.3 If yes, show the name of the state requiring suc	ch minimum capital and surplus.	Michigan
11.4 If yes, show the amount required.		\$62,356,337
11.5 Is this amount included as part of a contingence	y reserve in stockholder's equity?	Yes [] No [X]
11.6 If the amount is calculated, show the calculation	n	

4% of HMO subscription revenue - \$1,558,908,423 x 4% = \$62,356,337

12. List service areas in which reporting entity is licensed to operate:

1
Name of Service Area
Allegan
Barry
Clinton
Eaton
Genesee
Hillsdale
Huron
Ingham
lonia
Jackson
Kent
Lake
Lapeer
Lenawee
Livingston
Macomb
Mason
Mesosta
Monroe
Montcalm
Muskegon
Newaygo
0ak l and
Oceana
Osceola
Ottawa
St. Clair
Sanilac
Shi awassee
Tuscola
Washtenaw
Wayne
,

13.1 Do you act as a custodian for health savings accounts?

13.2 If yes, please provide the amount of custodial funds held as of the reporting date.

13.3 Do you act as an administrator for health savings accounts?

13.4 If yes, please provide the balance of the funds administered as of the reporting date.

14.1 Are any of the captive affiliates reported on Schedule S, Part 3 as authorized reinsurers?

14.2 If the answer to 14.1 is yes, please provide the following:

1	2	3	4	Assets Supporting Reserve Credit		
	NAIC Company	Domiciliary		5	6 Trust	7
Company Name	Code	Jurisdiction	Reserve Credit	Letters of Credit	Agreements	Other
	00000		<u> </u>			

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

15.1 Direct Premium Written

15. Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or

		15.2 Total Incurred Claims	\$
		15.3 Number of Covered Lives	
		*Ordinary Life Insurance Includes	
		Term (whether full underwriting, limited underwriting, jet issue, "short form app")	
		Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")	
		Variable Life (with or without secondary guarantee)	
		Universal Life (with or without secondary guarantee)	
		Variable Universal Life (with or without secondary guarantee)	
16.	Is the reporting entity licensed	or chartered, registered, qualified, eligible or writing business in at least two sta	ates? Yes [] No [X]
16.1	, ,	assume reinsurance business that covers risks residing in at least one state o	

FIVE - YEAR HISTORICAL DATA

	FIVE -	I EAR HIS				
		1 2023	2 2022	3 2021	4 2020	5 2019
Balar	nce Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	713,015,950	512,042,193	445,281,422	377,630,507	306,328,799
2.	Total liabilities (Page 3, Line 24)	476,420,841	334,502,887	293,190,210	243,442,915	183,231,239
3.			55,224,379	49,270,105	36,702,850	32,757,099
4.			177,539,306	152,091,212	134 , 187 , 592	123,097,560
Incon	ne Statement (Page 4)					
5.	Total revenues (Line 8)	1,558,987,051	1,380,691,401	1,231,791,768	917 ,820 ,463	819,082,274
6.	Total medical and hospital expenses (Line 18)	1,273,661,084	1, 151,774,937	1,030,080,913	714 , 441 , 240	644,406,059
7.	Claims adjustment expenses (Line 20)	39 , 957 , 822	35,953,791	32,376,977	31,665,431	27 , 664 , 140
8.	Total administrative expenses (Line 21)	174,301,270	162,926,405	149,911,108	157 , 018 , 356	124,055,645
9.	Net underwriting gain (loss) (Line 24)	48,681,534	30,036,268	19,422,770	16,995,436	20,656,430
10.	Net investment gain (loss) (Line 27)	21,378,991	6,629,556	67,200	1,670,646	4,598,849
11.	Total other income (Lines 28 plus 29)	0	0	0	0	0
12.	Net income or (loss) (Line 32)	51,705,363	28,989,589	15,199,813	12,286,616	19,728,440
Cash	Flow (Page 6)					
13.	Net cash from operations (Line 11)	59,882,464	(24,922,470)	103,718,635	105 , 787 , 936	39,449,563
Risk-	Based Capital Analysis					
14.	Total adjusted capital	236,595,109	177 , 539 , 306	152,091,212	134 , 187 , 592	123,097,560
15.	Authorized control level risk-based capital	48,004,691	46 , 113 , 162	40,818,489	28,734,611	25,829,625
Enrol	llment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)	330 , 174	349,588	324,160	289,577	209,910
17.	Total members months (Column 6, Line 7)	4,222,630	4,057,544	3 ,755 ,550	3,023,170	2,498,334
Opera	ating Percentage (Page 4)					
(Item	divided by Page 4, sum of Lines 2, 3, and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3	100.0	100.0	100.0	100.0	100.0
40	and 5) Total hospital and medical plus other non-health (Lines	100.0	100.0	100.0	100.0	100.0
19.	18 plus Line 19)	81.7	83.4	83.6	77.9	78.7
20.	Cost containment expenses	1.4	1.5	1.5	2.2	2.1
21.	Other claims adjustment expenses	1.1	1.1	1.1	1.3	1.2
22.	Total underwriting deductions (Line 23)	96.9	97.8	98.4	98.2	97.5
23.	Total underwriting gain (loss) (Line 24)	3.1	2.2	1.6	1.9	2.5
Unpa	id Claims Analysis					
(U&I I	Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	142,636,153	129 , 450 , 757	82,821,770	70,570,600	67,242,321
25.	Estimated liability of unpaid claims – [prior year (Line 17,	180,222,839	140 040 005	100 602 333	81 543 006	70 202 416
Invoc	Col. 6)] tments in Parent, Subsidiaries and Affiliates	100,222,039	149,949,990	109,002,333 1		
		0	0	0	0	0
26.	Affiliated preferred stocks (Sch. D Summary, Line 18,		0			0
21.	Col. 1)	0	0	0	0	0
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0	0	0
29.	Affiliated short-term investments (subtotal included in Sch. DA Verification, Col. 5, Line 10)	0				0
30.	Affiliated mortgage loans on real estate			0	0	0
31.			0	0	0	0
32.	Total of above Lines 26 to 31	0	0	0	0	0
33.	Total investment in parent included in Lines 26 to 31					
	above					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3 - Accounting Changes and Correction of Errors?......

If no, please explain

SCHEDULE T - PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

	Allocated by States and Territories 1 Direct Business Only										
		1	2	3	4	5	6	7	8	9	10
			Accident &				Federal Employees Health	Life & Annuity Premiums &	Property/	Total	
	State, Etc.	Active Status (a)	Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Benefits Plan Premiums	Other Considerations	Casualty Premiums	Columns 2 Through 8	Deposit-Type Contracts
1.	AlabamaAL	N.				-				0	0
2.	AlaskaAK	N	ļ							0	0
3.	Arizona AZ	N								0	0
4.	Arkansas AR	N								0	0
5.	California CA	N								0	0
6.	ColoradoCO	N.	ļ							0	0
7.	ConnecticutCT	N								0	0
8.	Delaware DE	N								0	0
9.	District of ColumbiaDC	N								0	0
10.	FloridaFL	N	 							0	0
11.	GeorgiaGA	N								0	0
12.	HawaiiHI	N								0	0
13.	IdahoID	N.								0	0
14.	IllinoisIL IndianaIN	NN.	·····							0	0
15. 16.										1	0
	lowa IA Kansas KS									0	0
17. 18.	Kentucky KY		·····							0	0
1	LouisianaLA	NN.	İ							0	n
20.	MaineME	N.	İ							0	n
21.	Maryland MD	NN.	İ							0	n
22.	Massachusetts MA	NN.								0	n
i	Michigan MI	L			1,558,908,423					1,558,908,423	n
24.	Minnesota MN	i			, , ,					1,000,000,420	n
25.	MississippiMS	N.								0	0
26.	Missouri MO									0	0
27.	Montana MT	N.								0	0
28.	NebraskaNE	N.								o	0
29.	NevadaNV	N								0	0
30.	New HampshireNH	N								0	0
31.	New Jersey NJ	N.								0	0
32.	New Mexico NM	N.								0	0
33.	New YorkNY	N								0	0
34.	North Carolina NC	N								0	0
35.	North DakotaND	N								0	0
36.	OhioOH	N								0	0
37.	OklahomaOK	N.	ļ							0	0
38.	Oregon OR	N.	ļ							0	0
39.	Pennsylvania PA	N								0	0
40.	Rhode Island RI	N								0	0
41.	South CarolinaSC	N.								0	0
42.	South DakotaSD	N								0	0
İ	TennesseeTN	N								0	0
44.	TexasTX	N	 							0	0
45.	UtahUT	N		l					L	0	0
46.	Vermont VT	N	 							0	0
1	Virginia VA	N								0	0
48. 49.	Washington WA West Virginia WV									0	0
1	WisconsinWI	NN.								0	0
1	Wyoming WY	1								0	n
51.	American SamoaAS	NN.							·	0	0
	GuamGU	NN.								0	0
54.	Puerto Rico PR	N.								I	0
i	U.S. Virgin Islands VI	N.								0	n
56.	Northern Mariana Islands MP	N.								I0	0
57.	CanadaCAN									I0	0
	Aggregate other alien OT	XXX	0	0	0	0	0	0	0	0	0
59.	Subtotal		0	0	1,558,908,423	0	0	0	0	1,558,908,423	0
60.	Reporting entity contributions for										
	Employee Benefit Plans									0	
61.	Total (Direct Business)	XXX	. 0	0	1,558,908,423	0	0	0	0	1,558,908,423	0
58001.	OF WRITE-INS	XXX									
58002.		XXX								İ	
58003.		XXX								ļ	
	Summary of remaining write-ins for Line 58 from overflow page		0	0	0	0	0	0	0	0	0
J0999.	Totals (Lines 58001 through 58003 plus 58998) (Line 58 above)	XXX	0	0	0	0	0	0	0	0	0
	abovej	ΛΛΛ		ı	U	U		ı ,	<u> </u>		

⁽b) Explanation of basis of allocation by states, premiums by states, etc. The Company has business in the state of Michigan only.




A nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association

STATEMENT AS OF DECEMBER 31, 2023 OF THE Blue Cross Complete of Michigan LLC SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATION CHART

BLUE CROSS BLUE SHIELD OF MICHIGAN MUTUAL INSURANCE COMPANY

EIN: 38-2069753



- 20% owned by BCS Financial Corporation.

- See pg. 40.3 for additional affiliates.
- 5 See pg. 40.4 for affiliated companies.
- 6 Pharmacy-Related Holdings Company, LLC owns a 20% stake of Evio Pharmacy Solutions, LLC.
- 7 Pharmacy-Related Holdings Company, LLC owns a 9.99% stake of InnovateRx LLC.
- 8 Innovate Rx LLC does not have an equity ownership in Civica Outpatient Subsidiary, LLC, which is a non-profit company. However, Innovate Rx LLC does have the right to appoint five managers to Civica Outpatient Subsidiary, LLC's board of managers which can range from 6 to 10 managers.
- 9 See pg. 40.5 for additional subsidiaries.
- 10 See pg. 40.6 for additional subsidiaries.

Blue Cross Blue Shield of Michigan Bargaining Unit Internal Health Benefit Trust EIN: 84-6869872

Blue Cross Blue Shield of Michigan Non-Bargaining Unit Internal Health Benefit Trust EIN: 84-6871980


> Blue Cross Blue Shield of Michigan Long-Term Disability Trust FIN: 81-6482696

Blue Cross Blue Shield of Michigan Employees' Retirement Master Trust EIN: 30-1140600

Blue Cross Blue Shield of Michigan 401 (K) MASTER TRUST EIN: 38-2069753-096



STATEMENT AS OF DECEMBER 31, 2023 OF THE Blue Cross Complete of Michigan LLC SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER OF A HOLDING COMPANY



NAIC: 17001

ND NAIC 16739

NAIC 16793

VT

All entities that do not reflect a particular state name or abbreviation are domiciled in Michigan.

¹ See page 40.2 for additional subsidiaries and affiliates.


² Emergient, Inc. owns a 51% stake in Vermont Blue Advantage LLC with the remaining 49% owned by Blue Cross and Blue Shield of Vermont.

³ Emergient, Inc. owns a 51% stake in Wellmark Advantage Holdings, LLC

⁴ Emergient, Inc. owns a 51% stake in NextBlue, LLC.




STATEMENT AS OF DECEMBER 31, 2023 OF THE Blue Cross Complete of Michigan LLC SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER OF A HOLDING COMPANY **GROUP**



All entities that do not reflect a particular state name or abbreviation are domiciled in Michigan.




STATEMENT AS OF DECEMBER 31, 2023 OF THE Blue Cross Complete of Michigan LLC SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER OF A HOLDING COMPANY GROUP





STATEMENT AS OF DECEMBER 31, 2023 OF THE Blue Cross Complete of Michigan LLC SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER OF A HOLDING COMPANY GROUP


PART 1 – ORGANIZATION CHART



- 1 Blue Cross Blue Shield of Michigan owns 10.1% of BCS Financial Corporation Accident Fund Insurance Company of America owns 3.56% of BCS Financial Corporation.
- 2 BCS Financial owns a 20% stake in LifeSecure Holdings Corporation with the remaining 80% owned by BCBSM.
- 3 BCS Financial Corporation owns 50% of Ancilyze Technologies LLC.



STATEMENT AS OF DECEMBER 31, 2023 OF THE Blue Cross Complete of Michigan LLC SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER OF A HOLDING COMPANY **GROUP**



India


FL

GloStream Inc. 401(k) Plan & Trust EIN: 34-2032238

- 1 GloStream Inc. owns a 50% stake in One Team Care, LLC.
 2 TRIARQ Health, LLC owns a 99.9999% stake in TRIARQ Health LLP and Glostream, Inc. owns 0.0001%.
- 3 TRIARQ Health, LLC owns a 68% stake in TRIARQ Health Alliance of Michigan.
- 4 Care Transformation Holding Company owns a 19.9% stake in Honest Medical of Michigan LLC



STATEMENT AS OF DECEMBER 31, 2023 OF THE Blue Cross Complete of Michigan LLC SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER OF A HOLDING COMPANY GROUP



- 1 Comprehensive Benefits Administrator, LLC owns a 50% stake in Cobalt Benefits Group, LLC.
- 2 Catamount Insurance Services, LLC owns a 50% stake in Vermont Collaborative Care, LLC.
- 3 Blue Cross and Blue Shield of Vermont owns a 49% stake in Vermont Blue Advantage, LLC with the remaining 51% owned by Emergient, Inc.